<SEC-DOCUMENT>0001213900-26-057939.txt : 20260515
<SEC-HEADER>0001213900-26-057939.hdr.sgml : 20260515
<ACCEPTANCE-DATETIME>20260515170704
ACCESSION NUMBER:		0001213900-26-057939
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		19
FILED AS OF DATE:		20260515
DATE AS OF CHANGE:		20260515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synergy CHC Corp.
		CENTRAL INDEX KEY:			0001562733
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				990379440
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295964
		FILM NUMBER:		26989635

	BUSINESS ADDRESS:	
		STREET 1:		865 SPRING STREET
		CITY:			WESTBROOK
		STATE:			ME
		ZIP:			04092
		BUSINESS PHONE:		615-939-9004

	MAIL ADDRESS:	
		STREET 1:		865 SPRING STREET
		CITY:			WESTBROOK
		STATE:			ME
		ZIP:			04092

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synergy Strips Corp.
		DATE OF NAME CHANGE:	20140429

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oro Capital Corporation, Inc.
		DATE OF NAME CHANGE:	20121121
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>ea0290954-s1_synergy.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on May 15, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 22pt 0pt 0; text-align: right"><B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></b></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1<BR>
REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synergy CHC Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact Name of Registrant as Specified in its
Charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>2833</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>99-0379440</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><I>(State or
other jurisdiction of<BR>
incorporation or organization)</I></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(Primary Standard Industrial<BR>
Classification Code Number)</I></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(I.R.S.&nbsp;Employer<BR>
Identification No.)</I></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>770 Roosevelt Trail STE 8 #1016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N. Windham, Maine 04062<BR>
(207) 321-2350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jack Ross<BR>
Chief Executive Officer<BR>
c/o Synergy CHC Corp.<BR>
770 Roosevelt Trail STE 8 #1016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N. Windham, Maine 04062 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(207) 321-2350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Copies to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>W. David Mannheim<BR> Michael K. Bradshaw, Jr.<BR> Nelson Mullins Riley &amp; Scarborough LLP<BR> 301 Hillsborough Street, Suite 1400<BR> Raleigh, NC 27603<BR> (919) 329-3800</B></FONT> &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Approximate date of commencement
of proposed sale to public: <B>From time to time after this registration statement becomes effective.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">If any of the securities being
registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act&nbsp;of&nbsp;1933,
check the following box. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">If this Form is filed to register
additional securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">If this Form is a post-effective
amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">If this Form is a post-effective
amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Non-accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Emerging&nbsp;growth&nbsp;company</FONT></TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B>The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further
amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities Exchange
Commission, acting pursuant to section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>The information contained
in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the Registration Statement
filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities.
Neither we nor the selling stockholder are soliciting offers to buy these securities in any state where the offer or sale is not permitted.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>&nbsp;</B></FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 30%"><FONT STYLE="font-size: 10pt; color: Red"><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; width: 2%"><FONT STYLE="color: Red">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 36%"><FONT STYLE="font-size: 10pt; color: Red"><B>SUBJECT TO COMPLETION</B></FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; width: 2%"><FONT STYLE="color: Red">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 30%"><FONT STYLE="font-size: 10pt; color: Red"><B>DATED MAY 15, 2026</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>101,710,000 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029095401_img1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synergy CHC Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus relates to
the resale from time to time of up to 101,710,000 shares of common stock, par value $0.00001 (the &ldquo;common stock&rdquo;), of Synergy
CHC Corp., a Nevada corporation (the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; and &ldquo;us&rdquo;), by Hudson Global
Ventures, LLC (the &ldquo;Selling Stockholder&rdquo;). The 101,710,000 shares of common stock registered under the registration statement
of which this prospectus forms a part (the &ldquo;Registration Statement&rdquo;) consists of (i) 100,000,000 shares of common stock (the
&ldquo;ELOC Shares&rdquo;) issued to the Selling Stockholder as a result of the Company directing the Selling Stockholder to purchase
such shares from time to time pursuant to an Equity Purchase Agreement dated May 8, 2026 (the &ldquo;ELOC Purchase Agreement&rdquo;),
(ii) 1,540,000 shares of common stock (the &ldquo;Warrant Shares&rdquo;) issuable upon the exercise of a warrant (the &ldquo;Warrant&rdquo;)
issued to the Selling Stockholder as a commitment fee upon the execution of the ELOC Purchase Agreement, and (iii) shares of common stock
previously issued to the Selling Stockholder in connection with the consulting agreements between Selling Stockholder and the Company (the
&ldquo;Existing Shares&rdquo;). See the section of this prospectus entitled &ldquo;<I>The ELOC Purchase Agreement</I>&rdquo; for a description
of the terms and conditions of the ELOC Purchase Agreement, including the Warrant Shares and the Warrant.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The Selling Stockholder may
sell the shares of common stock described in this prospectus in a number of different ways and at varying prices determined by the prevailing
market price for the shares or in negotiated transactions. We are not selling any securities under this prospectus and will not receive
any of the proceeds from the sale of shares of common stock by the Selling Stockholder. However, we may receive up to $36,000,000 in
aggregate gross proceeds under the ELOC Purchase Agreement. We provide more information about how the Selling Stockholder may sell its
shares of common stock in the section of this prospectus entitled &ldquo;<I>Plan of Distribution</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B>The Selling Stockholder
is an &ldquo;underwriter&rdquo; within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;) with respect to the resale of its shares of common stock hereunder. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We will pay the expenses incurred
in registering the common stock described in this prospectus, including legal and accounting fees. To the extent the Selling Stockholder
decides to sell its shares of common stock, we will not control or determine the price at which the shares are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our common stock is listed
on the Nasdaq Capital Market under the symbol &ldquo;SNYR&rdquo;. The last reported sale price of our common stock on Nasdaq on May 13,
2026, was $0.30 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We may amend or supplement
this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments
or supplements carefully before you make your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We are a &ldquo;smaller reporting
company&rdquo; as defined in the federal securities laws and will be subject to reduced public company reporting requirements. See &ldquo;<I>Prospectus
Summary &mdash; Implications of Being a Smaller Reporting Company</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B>Investing in our common
stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 9 of this prospectus and under similar headings
in the documents incorporated by reference into this prospectus for a discussion of information that should be considered in connection
with an investment in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; width: 90%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">SELLING STOCKHOLDER</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">THE ELOC PURCHASE AGREEMENT</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">This prospectus is part of
a registration statement on Form S-1 that we have filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) pursuant to
which the Selling Stockholder may, from time to time, offer and sell or otherwise dispose of the shares of our common stock described
in this prospectus. We will not receive any proceeds from the sale by the Selling Stockholder of the shares of our common stock offered
by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We may also file a prospectus
supplement or post-effective amendment to the Registration Statement that may contain material information relating to this offering.
The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus. If there
is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment,
you should rely on the prospectus supplement or post-effective amendment, as applicable. The Registration Statement includes exhibits
that provide more detail regarding the matters discussed in this prospectus. You should read this prospectus, any post-effective amendment,
and any applicable prospectus supplement and the related exhibits filed with the SEC before making your investment decision. The Registration
Statement and the exhibits can be obtained from the SEC, as indicated under the section entitled &ldquo;<I>Where You Can Find More Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We incorporate by reference
important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions
under &ldquo;<I>Where You Can Find More Information</I>.&rdquo; You should carefully read this prospectus as well as additional information
described under &ldquo;<I>Incorporation of Certain Information By Reference</I>&rdquo; before deciding to invest in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">You should rely only on the
information contained in this prospectus and any applicable prospectus supplement or post-effective amendment. We have not authorized
anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely
on it. The information contained in this prospectus is accurate only as of the date of this prospectus and the information contained in
any prospectus supplement or post-effective amendment is accurate only as of the date of that document. Our business, financial condition,
results of operations and prospects may have changed since those dates. Other than as required under the federal securities laws, we undertake
no obligation to publicly update or revise any information in this prospectus, any prospectus supplement or any post-effective amendment,
whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">This prospectus does not constitute
an offer to sell or the solicitation of an offer to buy any of our securities other than the securities covered hereby, nor does this
prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom
it is unlawful to make such offer or solicitation in such jurisdiction. Persons who come into possession of this prospectus in jurisdictions
outside the United States are required to inform themselves about, and to observe, any restrictions as to the offering and the distribution
of this prospectus applicable to those jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">This prospectus contains summaries
of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to
herein have been filed, will be filed, or will be incorporated by reference as exhibits to the registration statement of which this prospectus
is a part, and you may obtain copies of those documents as described below under the sections entitled &ldquo;<I>Where You Can Find More
Information</I>&rdquo; and &ldquo;<I>Incorporation of Certain Information by Reference</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Trademarks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We own or have rights to various
trademarks, service marks and trade names that we use in connection with the operation of our business. This prospectus and the information
incorporated by reference herein may also contain trademarks, service marks and trade names of third parties, which are the property of
their respective owners. Our use or display of third parties&rsquo; trademarks, service marks and trade names or products in this prospectus
or information incorporated by reference herein is not intended to, and does not imply a relationship with, or endorsement or sponsorship
by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus or in the information incorporated
by reference herein may appear without the <SUP>&reg;</SUP>, <SUP>TM</SUP>&nbsp;or <SUP>SM</SUP>&nbsp;symbols, but the omission of such
references is not intended to indicate, in any way, that we will assert, to the fullest extent under applicable law, our rights or the
right of the applicable owner of these trademarks, service marks and trade names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market and Industry Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Unless otherwise indicated,
information contained and incorporated by reference in this prospectus concerning our industry, competitive position and the markets in
which we operate is based on information from independent industry and research organizations, other third-party&nbsp;sources and management
estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third-party&nbsp;sources,
as well as data from our internal research, and are based on assumptions we made upon reviewing such data, and our experience in, and
knowledge of, such industry and markets, which we believe to be reasonable. In addition, projections, assumptions and estimates of the
future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due
to a variety of factors, including those described in the sections entitled &ldquo;<I>Risk Factors</I>&rdquo; and &ldquo;<I>Cautionary
Note&nbsp;Regarding Forward-Looking&nbsp;Statements</I>&rdquo; contained or incorporated by reference in this prospectus. These and other
factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">This prospectus and the documents
incorporated by reference into this prospectus include statements that express our opinions, expectations, beliefs, plans, objectives,
assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, &ldquo;forward-looking
statements.&rdquo; All statements other than statements of historical facts contained in this prospectus and the documents incorporated
by reference into this prospectus may be forward-looking statements. These forward-looking statements can generally be identified by the
use of forward-looking terminology, including the terms &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;continues,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;expects,&rdquo; &ldquo;seeks,&rdquo; &ldquo;projects,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;would&rdquo; or &ldquo;should&rdquo; or, in each case, their negative or other variations or comparable terminology. They appear
in a number of places throughout this prospectus and the documents incorporated by reference into this prospectus, and include statements
regarding our intentions, beliefs or current expectations concerning, among other things, our results of operations, financial condition,
liquidity, prospects, growth, strategies, future acquisitions and the industry in which we operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">By their nature, forward-looking
statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the
future. We believe that these risks and uncertainties include, but are not limited to, those described in the &ldquo;<I>Risk Factors</I>&rdquo;
section of this prospectus and under similar headings in the documents incorporated by reference into this prospectus, which include,
but are not limited to, risks related to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our ability to compete in our industry, including against competitors
that have significantly greater financial, technical and marketing resources than we do;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to respond to customer preferences and successfully
develop new and innovative products in a timely manner and effectively manage the introduction of new or enhanced products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">risks related to a loss of, or material cancellation, reduction,
or delay in purchases by, one or more of our largest customers;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our outside suppliers and manufacturers failing to supply products
in sufficient quantities and in a timely fashion;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to execute on our strategic initiatives (including
acquisitions);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to maintain the reputation of our brands;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the risks related to consumers&rsquo; perception of the safety
and quality of our products as well as similar products distributed by other companies in our industry;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the risks related to third parties asserting intellectual property
infringement claims against us;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the risks related to our planned expansion into additional international
markets;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the risks related to adverse economic conditions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the risks related to catastrophic events;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to retain key personnel, manage our business effectively,
and continue to grow;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the impact of numerous laws and regulations that apply to the
manufacture and sale of nutritional supplements, and compliance with these laws and regulations, as they currently exist or as modified
in the future, on us and our suppliers;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the risks related to product recalls;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the risks related to product liability claims and litigation
to prosecute such claims; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the other factors described in &ldquo;<I>Risk Factors</I>.&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">These factors should not be
construed as exhaustive and should be read with the other cautionary statements in this prospectus and the documents incorporated by reference
into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Although we base these forward-looking
statements on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees
of future performance and that our actual results of operations, financial condition and liquidity, and industry developments may differ
materially from statements made in or suggested by the forward-looking statements contained in this prospectus and the documents incorporated
by reference into this prospectus. The matters summarized under &ldquo;<I>Prospectus Summary</I>,&rdquo; &ldquo;<I>Risk Factors</I>,&rdquo;
&ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>,&rdquo; &ldquo;<I>Business</I>&rdquo;
and elsewhere in this prospectus and in the documents incorporated by reference into this prospectus could cause our actual results to
differ significantly from those contained in our forward-looking statements. In addition, even if our results of operations, financial
condition and liquidity, and industry developments are consistent with the forward-looking statements contained in this prospectus and
the documents incorporated by reference into this prospectus, those results or developments may not be indicative of results or developments
in subsequent periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">In light of these risks and
uncertainties, we caution you not to place undue reliance on these forward-looking statements. Any forward-looking statement that we make
in this prospectus and the documents incorporated by reference into this prospectus speaks only as of the date of such statement, and
we undertake no obligation to update any forward-looking statement or to publicly announce the results of any revision to any of those
statements to reflect future events or developments, except as required by applicable law. Comparisons of results for current and any
prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such,
and should only be viewed as historical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><I>This summary highlights
information contained in greater detail elsewhere or incorporated by reference in this prospectus and does not contain all of the information
that you should consider before deciding to invest in our common stock. You should read the entire prospectus carefully, including the
&ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and our consolidated financial statements and the related notes incorporated by reference in this prospectus, before making an investment
decision. Some of the statements included in this prospectus and the information incorporated by reference herein constitute&nbsp;forward-looking&nbsp;statements.
See &ldquo;Cautionary Note&nbsp;Regarding&nbsp;Forward-Looking&nbsp;Statements.&rdquo; Unless otherwise indicated in this prospectus,
&ldquo;Synergy CHC,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Synergy CHC Corp. and, where appropriate,
its subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We are a provider of consumer
health care, beauty, and lifestyle products. Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested
brain health supplement (this study was performed independently and is not related to any U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
-approved investigational new drug (IND) application) that has been shown to improve memory, concentration and focus, and Flat Tummy,
a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management
goals. Collectively, these brands are referred to as nutraceuticals. Our products are sold through some of the nation&rsquo;s leading
club, mass drug, and other retailers such as Costco, Amazon.com, Walmart, Walgreens, BJ&rsquo;s, and The Vitamin Shoppe. Additionally,
we have expanded into Canada and Mexico.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We built our brand portfolio
through strategic acquisitions. We acquired the FOCUSfactor brand in January 2015 for cash consideration of $6.0 million, including earnout.
In November 2015, we acquired our second marquee brand, Flat Tummy, for AUD 10.0 million (approximately $7.0 million), using a mix of
cash and stock. Our capital structure following the acquisitions of our key brands in 2015 has been highly levered, and our focus has
been on paying our debt and, as a result, we do not have the resources to grow our business. We have grown our FOCUSfactor brand from
3 SKUs at acquisition to over 34 SKUs, and our Flat Tummy Brand from 1 SKU to 13 SKUs. We use the term SKU, or stock-keeping unit, to
refer to a product with a unique UPC (Universal Product Code), which is the barcode used to identify products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We intend to accelerate the
growth of both our FOCUSfactor supplements and FOCUSfactor energy Ready To Drink (RTD) products. Our asset-light business model, in which
we partner with third-party manufacturers to produce our brand offerings, allows us to scale quickly and profitably while satisfying growing
demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">For the year ended December&nbsp;31, 2025, our revenue, net income
and EBITDA were $30.4&nbsp;million, $(12.3)&nbsp;million and $(6.2)&nbsp;million, respectively, as compared to $34.8&nbsp;million, $2.1&nbsp;million
and $6.5&nbsp;million for the prior year. The EBITDA decrease in 2025 was due to the decrease in net income due to many one-time items,
which reduced net income, including a reserve of bad debt of $6.7 million and write-off of inventory of $0.9 million. At December&nbsp;31,
2024 we had a working capital deficit of $1.1&nbsp;million. At December 31, 2025 we had a working capital surplus of $1.8&nbsp;million.
For reconciliation of EBITDA to net income (loss) see &ldquo;&mdash; <I>Non</I>-<I>GAAP Financial Measures</I>&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Brands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our flagship brand, FOCUSfactor,
is a brain health nutritional supplement with over 25 years of history and a clinically-tested formula (this study was performed independently
and is not related to any FDA-approved IND application) comprised of a proprietary blend of key brain supporting ingredients along with
vitamins, minerals, and other nutrients. We believe FOCUSfactor is the only product in its category whose entire formula has been shown
to support memory, concentration and focus. Our FOCUSfactor brand consists of over 34 SKUs and is sold primarily through leading retailers
in the United States, including Costco, Amazon.com, Walmart, Walgreens, BJ&rsquo;s, and The Vitamin Shoppe, in addition to selling direct
to consumer through the FOCUSfactor website. Across three of our key partners, we have increased the number of SKUs sold through the
retailer from the single SKU available at the beginning of our relationships in 2015 and 2016. In addition, we have increased our presence
in retail locations for these key partners, resulting in a significant increase in points of distribution, defined as the number of SKUs
multiplied by the number of retail locations for each retailer. We have also expanded the brand internationally into Canada (2020) and
Mexico (2025).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">FOCUSfactor has expanded into
the beverage market with its focus plus energy RTD. According to Zion Research in January 2024, the global beverage market is large ($176
billion in 2022) and growing (projected 8.6% CAGR covering eight years from 2022 through 2030) with an expanding range of functional benefits
such as energy, hydration, cognition/focus, weight loss, gut health and immunity. Examples such as Celsius and Beyond Raw offer dual-benefit
products that deliver fat burning plus energy while C4 Smart Energy and FocusAid deliver focus plus energy. Additionally, consumers are
looking for not only refreshing drinks but health perks such as zero sugar and low-calorie drinks. This consumer shift in preferences
towards more functional benefits can be seen in the evolution of the energy RTD category where originally competitors like Red Bull and
Monster delivered conventional energy, then the category offered more performance energy products with added vitamins and amino acids
in products such as Reign and C4 Performance to products with more natural energy characteristics and then to the dual-benefit energy
products that we see today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">FOCUSfactor is well-positioned
to capitalize on the evolving energy RTD category (U.S. sales of $19.2 billion in 2023 and a CAGR of 6.3% from 2018 to 2023, according
to Euromonitor in December 2023) with its new focus plus energy RTD. We believe this represents a major growth opportunity, with our dual-benefit
RTD formula offering both focus and energy behind a 24+ year brand with strong heritage and awareness in the area of brain health. The
FOCUSfactor brand name clearly communicates the differentiation benefit of adding focus to energy. The FOCUSfactor formula does not have
to rely as heavily on caffeine as other brands such as Celsius, Bang, Reign and C4, as its formula is a balanced blend of vitamins, cognitive
nutrients and caffeine all in a zero sugar, low calorie, great-tasting drink. The brand also delivers a significant value relative to
many competitors. Additionally, FOCUSfactor has long-term relationships with large retailers where it has an established presence, which
will assist in market penetration for its RTD products. FOCUSfactor is looking to attract both existing consumers of supplement products
(typically customers over age 50) to RTDs as well as a younger demographic (aged 18-49).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">FOCUSfactor has successfully
demonstrated the ability to leverage its existing retailer relationships to expand its RTDs. From March 2023 through August 2023, FOCUSfactor
conducted a five-month trial of its RTD products in 44 clubs of a warehouse club retailer throughout Texas with sales ranging from $550
per club per week to $2,382 per club per week. From April 2024 through July 2024, a second pilot was successfully completed at a major
Canadian club retailer throughout Canada with results ranging from C$378 per club per week to C$2,206 per club per week.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea029095401_img2.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P></DIV>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our second marquee brand, Flat
Tummy, consists of a range of lifestyle and wellness products and accessories including tea, shakes, lollipops, supplements, apparel,
and exercise accessories. We also provide a Flat Tummy mobile app, which, as of December 31, 2025, had approximately 2.0 million unique
downloads and is intended as a tool to promote the Flat Tummy lifestyle centered around general wellness and health. Our Flat Tummy brand
consists of 13 SKUs and is sold direct to consumer through the Flat Tummy website and application, as well as through Amazon.com, Target.com
and iherb.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea029095401_img3.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also own six additional,
non-core&nbsp;brands. While we may elect to promote these brands and commercialize their products in the future, we have prioritized our
key brands, FOCUSfactor and Flat Tummy, and management is focused on the growth of these core products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our net revenues by brand for
the year ended December 31, 2025 are below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029095401_img4.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">In the United&nbsp;States,
the U.S.&nbsp;Food and Drug Administration (the &ldquo;FDA&rdquo;) has regulatory oversight over our FOCUSfactor and Flat Tummy products.
However, no formal FDA approval or registration is required because our products are classified as dietary supplements (most FOCUSfactor
products and some Flat Tummy products) or foods (some FOCUSfactor and Flat Tummy products).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">In Canada, Health Canada (&ldquo;HC&rdquo;)
has oversight over our FOCUSfactor and Flat Tummy products. Our FOCUSfactor and Flat Tummy products are considered natural health products
by HC so they each have a natural product number that was assigned by HC upon its review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">In Australia, FOCUSfactor products
are &ldquo;Listed Medicines&rdquo; that are regulated by the Therapeutic Goods Administration (&ldquo;TGA&rdquo;) and require an AUST
L (Australia Listed Medicine) number, which has been received for some SKUs. Flat Tummy products are classified as either Listed Medicines
or meal replacements. Listed Medicines are regulated by the TGA while meal replacements are regulated under the Australia New Zealand
Food Standards Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We believe that we have attributes
that differentiate us from our competitors and provide us with significant competitive advantages. Our key competitive strengths include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Well-Positioned&nbsp;in Growing Categories
Driven by Favorable Consumer Trends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">An increased focus on health,
beauty and wellness by consumers has served as a tailwind for our brands. The nutritional supplement market has experienced significant
growth across a range of areas including immune health, brain health, heart health, sleep/stress, and overall nutrition and wellness as
a result of an aging population, increased obesity, pandemic concerns and a desire for more natural solutions and treatments over prescription
medication. We believe that we are well positioned to benefit from these favorable trends. The brain health segment is slated to grow
at 8% per year in the United States and 13% per year globally through 2030, according to Grand View Research. We believe our focus on
lifestyle products has also benefited from the growth and prevalence of social media.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Results Backed by Independent Study for
FOCUSfactor</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We believe the FOCUSfactor
brand is strengthened by an independent clinical study to support the product claims for improved memory, concentration, and focus. FOCUSfactor
has been tested in a single-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate its effect on memory,
concentration, and focus in healthy adults. The study was not a clinical trial conducted pursuant to an FDA-approved IND application,
and the FDA has not reviewed this study or evaluated these performance claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">In this study, FOCUSfactor
was tested on its entire 52-ingredient formulation rather than testing one or two ingredients within a formulation. FOCUSfactor was shown
to provide a 44% increase in recall memory (an increase of 6.5 words compared to 4.5 words for the placebo group) after six weeks of use
versus placebo. This differentiates FOCUSfactor from other brain-health supplements and is a prime reason why FOCUSfactor has been placed
in premier retailers. This controlled study was conducted in healthy male and female subjects between the ages of 18 and 65 who were randomized
in a control group and a placebo group. Subjects were compensated for their participation. See the section entitled &ldquo;<I>Business&nbsp;&mdash;&nbsp;FOCUSfactor
Study</I>&rdquo; in the documents incorporated by reference into this prospectus for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Experienced Management Team with Proven
Track Record of Value Creation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our executive team has a combined
90&nbsp;years of experience in consumer marketing and distribution and has been instrumental in acquiring and building our core brands.
Management has exercised strong financial discipline in its acquisition strategy, with a focus on acquiring brands at attractive valuations.
For example, we acquired FOCUSfactor for approximately 3x trailing EBITDA.&nbsp;For the year ended December&nbsp;31, 2025 and year ended
December&nbsp;31, 2024, FOCUSfactor generated net revenue of $27.8&nbsp;million and $30.7&nbsp;million, respectively. Management&rsquo;s
philosophy is to acquire promising brands that fit within our health, beauty and lifestyle offerings, and apply our marketing and distribution
strategies to develop brands to their full potential. We believe we are adept at identifying promising opportunities that build out and
complement our core brand portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Premier Retail Partners</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our premier retail partners
include Costco, Amazon.com, Walmart, Walgreens, BJ&rsquo;s, and The Vitamin Shoppe and others. We sell products to these partners under
their standard arrangements, which do not include a term or duration as sales under each vendor agreement are generally made on a purchase
order basis. Our partners provide a platform to expand the breadth of our current offerings through product line extensions and new product
innovation. We continue to introduce new SKUs to our current retail partners, such as the addition of FOCUSfactor RTDs and vision products
to these retail partners and other channels. Additionally, the international footprint of certain of our various retail partners facilitates
our geographic expansion plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Scalable and Flexible&nbsp;Asset-Light&nbsp;Model
to Support Growth</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our focus is on brand management,
marketing, product development and distribution, and we utilize contract manufacturing partners in order to produce our various brand
offerings. The use of third-party manufacturing partners allows us to scale quickly, as we ensure that our partners have sufficient capacity
to meet our demand needs. We also maintain multiple relationships with different contract manufacturers, ensuring diversification of our
manufacturing base and reducing the likelihood of supply bottlenecks or deficits that could potentially slow our growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We intend to drive growth and
increased profitability in our business through these key elements of our strategy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Broaden Media Advertising Strategy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We have experienced significant
acceleration in sales growth for the FOCUSfactor brand as a result of our television advertising in prior years. We launched a national
advertising campaign in August 2020, which aired on major news and entertainment networks such as Fox News, CNN, MSNBC, TLC, and TNT,
targeting adults 45 years of age and older. We anticipate a coordinated expansion of our advertising strategy during 2026, as we focus
on pushing additional SKUs within our retail sales partner network to continue to build brand awareness and increase reach for FOCUSfactor.
We also plan to continue to invest in online marketing to promote all of our brands, including social media and influencer driven marketing.
We have also experienced significant growth through our increased distribution, which we continue to drive forward.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acquire Brands which Complement Our Existing
Portfolio</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We will continue to evaluate
acquisition opportunities that we believe fit well within our brand portfolio and create value for our stockholders, such as further retail
expansion in nutraceuticals and market expansion in health and beauty. In spite of historical capital constraints, our opportunistic approach
to acquisitions has resulted in a successful track record of identifying promising targets that align with our overall brand strategy
in the health, beauty and lifestyle segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Partner with Additional Leading Retailers
to Expand the Reach of Our Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Based on the success of our
products with our established leading retail partners, we believe that we are well positioned to add new retailers that will enhance our
distribution footprint. We believe we have expansion opportunities with food retailers, including those focused on health foods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Diversify Our Geographic Presence through
Entry into New Markets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We seek to accelerate our sales
growth by expanding and further diversifying our geographic footprint. For the year ended December 31, 2025, substantially all of our
revenue was generated within North America. Our goal is to increase our revenues generated from new markets. As we target new international
markets, our strategy is to develop highly competitive and differentiated products that are produced in-country for ease of entry, with
support from our regulatory group and an in-country regulatory consultant to help expedite the approval process. We entered the Mexico
market in the fourth quarter of 2025 and plan to enter Taiwan and Asia in 2026, initially with FOCUSfactor, followed by Flat Tummy. We
then plan to expand our brands into Australia (where we have Therapeutic Goods Administration (&ldquo;TGA&rdquo;) approval for our FOCUSfactor
products). In addition, we are developing our marketing plans in compliance with applicable law and are initiating retailer meetings as
we seek to gain distribution across these new retail markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Use Innovative Strategies to Boost Consumer
Engagement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We have made investments in
promoting an app for Flat Tummy and view this as a key aspect of growing our customer base and maintaining high levels of engagement.
We have also focused on developing our social media presence, in particular through Instagram, in order to foster and grow our relationship
with customers. Our brands appeal to both specific consumer needs as well as lifestyle choices and we seek to deepen our understanding
of our customers and boost recognition of our brands through increased engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Continue to Develop and Expand Our Current
Brands</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our plan is to further develop
and expand our brands by reaching a broader set of customers through advertising and product expansion. More specifically, we look to
develop new products for our brands to satisfy the various customer segment opportunities (i.e., baby boomers, millennials, etc.) and
satisfy various consumer needs as they relate to new and improved formulations, expanded and improved product benefits, alternative delivery
formats and sizes. As we increase the product line-up behind our brands, we leverage our current retail distribution network by expanding
our presence as well as adding incremental distribution with new retail partners. With a broader brand presence, we believe our advertising
becomes even more efficient at driving sales velocity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">This is evidenced by our expanded
FOCUSfactor product line, including focus and energy RTD and liquid shots that are marketed to a younger adult audience. In 2023, we successfully
launched an RTD pilot program in the United States through a major retailer. Additionally, in the second quarter of 2024, we launched
three core FOCUSfactor focus and energy RTD products in Canada. In the first quarter of 2025, we introduced new complementary products
to the Flat Tummy line-up, including new protein shakes, GLP-1 support products and pre-workout powders. In the fourth quarter of 2025,
we introduced FOCUSfactor to Mexico.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Marketing and Sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our targeted, consumer-driven&nbsp;marketing
strategy has been key to building our brands and driving revenue growth. We manage dedicated marketing strategies for each of our brands
in order to build deep connections with our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B><I>FOCUSfactor.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Our
marketing strategy for FOCUSfactor is primarily focused on increased distribution and advertising campaigns that appeal to the demographics
of our wellness focused customer base. For the year ended December&nbsp;31, 2025, FOCUSfactor net revenue decreased 10% year-over-year,
to $27.8&nbsp;million, primarily due to the rebranding and packaging upgrade we undertook. As our flagship brand, FOCUSfactor accounted
for 92% of our net revenue in the year ended December 31, 2025, compared with 88% in the year ended December&nbsp;31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><B><I>Flat Tummy.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>We
employ a primarily online and social media driven strategy for our Flat Tummy brand. The brand is focused primarily on women. We employ
campaigns to reach our core target segments through a mix of traditional online advertising as well as influencer-based&nbsp;marketing.
For the year ended December 31, 2025, Flat Tummy accounted for 8% of our net revenue, compared with 12% of our net revenue in the year
ended December&nbsp;31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The U.S. nutritional supplements
retail industry is a large and highly fragmented industry with few barriers to entry. We compete against other domestic and international
manufacturers, specialty retailers, mass merchants, multi-level marketing organizations, mail-order and direct-to-consumer companies,
and e-commerce companies. This market is highly sensitive to the introduction of new products, which may rapidly capture a significant
share of the market. Certain of our competitors may have significantly greater financial, technical and marketing resources than we do,
and may be able to adapt to changes in consumer preferences more quickly, devote greater resources to the marketing and sale of their
products, or generate greater brand recognition. In addition, our competitors may be more effective and efficient in introducing new products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Although there are many competing
products on the market across our product categories, we believe that the FOCUSfactor brand is strengthened by an independent study to
support its claim of improving memory, concentration and focus. FOCUSfactor&rsquo;s competitors include a wide range of products, from
targeted brain-enhancement supplements to indirect competitors such as energy drinks that claim to improve concentration. Our Flat Tummy
brand competes in well-established segments with a diverse range of competition both domestically and internationally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Non-GAAP Financial Measures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We currently focus on EBITDA
to evaluate our business relationships and our resulting operating performance and financial position. EBITDA is defined as net income
plus interest expense, income tax expense, depreciation and amortization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We believe that EBITDA, viewed
in addition to, and not in lieu of, our reported results in accordance with accounting principles generally accepted in the United&nbsp;States
(&ldquo;U.S.&nbsp;GAAP&rdquo;), provides useful information to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <BR> December&nbsp;31, <BR> 2025</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <BR> December&nbsp;31, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(12,341,208</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,124,976</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,065</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,523</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,919,742</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,105,198</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,471</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,085</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Depreciation and amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">133,334</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">133,334</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">EBITDA</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6,185,726</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,464,070</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">EBITDA is considered a non-GAAP
financial measure. EBITDA represents earnings before interest, taxes, depreciation and amortization. Our definition of EBITDA might not
be comparable to similarly titled measures reported by other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">An investment in our common
stock involves a high degree of risk. You should carefully consider the risks summarized below. These risks are discussed more fully in
the section titled &ldquo;<I>Risk Factors</I>&rdquo; following this prospectus summary and under similar headings in the documents incorporated
by reference into this prospectus. These risks include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We operate in a highly competitive industry and our failure
to compete effectively could materially and adversely affect our sales and growth prospects;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our failure to appropriately respond to changing consumer preferences
and demand for new products or product enhancements could significantly harm our relationship with customers and our product sales, as
well as our financial condition and operating results;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our sales growth is dependent upon maintaining our relationships
with a small number of existing large customers, and the loss of any one such customer could materially adversely affect our business
and financial performance;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">If our outside suppliers and manufacturers fail to supply products
in sufficient quantities and in a timely fashion, our business could suffer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Adverse or negative publicity could cause our business to suffer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We continue to explore new strategic initiatives, but we may
not be able to successfully execute on, or realize the expected benefits from, the implementation of our strategic initiatives, and our
pursuit of new strategic initiatives may pose significant costs and risks;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The nutritional supplement industry increasingly relies on intellectual
property rights and although we seek to ensure that we do not infringe the intellectual property rights of others, there can be no assurance
that third parties will not assert intellectual property infringement claims against us;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We plan to expand into additional international markets, which
will expose us to significant operational risks;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We may experience product recalls, withdrawals or seizures,
which could materially and adversely affect our business, financial condition and results of operations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We and our suppliers are subject to numerous laws and regulations
that apply to the manufacturing and sale of nutritional supplements, and compliance with these laws and regulations, as they currently
exist or as modified in the future, may increase our costs, limit or eliminate our ability to sell certain products, subject us or our
suppliers to the risk of enforcement action or litigation, or otherwise adversely affect our business, results of operations and financial
condition; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The other factors described in &ldquo;<I>Risk Factors</I>.&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being a Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We are a &ldquo;smaller reporting
company&rdquo; as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting
companies so long as the market value of our voting and non-voting common stock held by non-affiliates is less than $250.0&nbsp;million
measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most
recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700.0&nbsp;million measured
on the last business day of our second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We were organized as a corporation
under the laws of the State of Nevada on December&nbsp;29, 2010 under the name &ldquo;Oro Capital Corporation.&rdquo; In April&nbsp;2014,
Synergy Strips Corp., a Delaware corporation, became our wholly-owned&nbsp;subsidiary, and we changed our name from &ldquo;Oro Capital
Corporation&rdquo; to &ldquo;Synergy Strips Corp.&rdquo; In August&nbsp;2015, we changed our name to &ldquo;Synergy CHC Corp.&rdquo; In
January&nbsp;2019, our other U.S.&nbsp;subsidiaries, Neuragen Corp., Sneaky Vaunt Corp., The Queen Pegasus Corp. and Breakthrough Products
Inc., merged with and into the Company. Synergy is the sole owner of four subsidiaries: NomadChoice Pty Ltd., Hand MD Corp., Synergy CHC
Inc. and Synergy CHC Mexico, and the results have been consolidated in these statements. Synergy CHC Mexico was incorporated during May
2025 for the purposes of expanding into Mexico.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We completed our initial public
offering on October&nbsp;24, 2024, and became subject to the information and reporting requirements of the Exchange&nbsp;Act. We file
periodic reports, proxy statements and other information with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The address of our principal
executive offices is currently 770 Roosevelt Trail STE 8 #1016, N. Windham, Maine 04062 and our phone number is (207)&nbsp;321-2350. Our
website is&nbsp;<I>www.synergychc.com</I>. The information contained in, or that can be accessed through, our website is not incorporated
by reference in, and is not part of, this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</DIV>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 23%"><B>Securities Offered by Selling Stockholder</B></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 3%">&#9679;</TD>
  <TD STYLE="width: 72%">up to 100,000,000 ELOC Shares;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>up to 1,540,000 Warrant Shares; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD>170,000 Existing Shares.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 23%"><FONT STYLE="font-size: 10pt"><B>Shares of common stock outstanding prior to this offering</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-size: 10pt">14,899,883&nbsp;shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt"><B>Common stock to be outstanding after this offering</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">116,439,883 shares assuming the sale of all of the ELOC Shares and
Warrant Shares registered under the Registration Statement. The actual number of shares issued will vary depending on the sales prices
in this offering, but will not be greater than 2,978,486 shares (including the Warrant Shares), representing 19.99% of the shares of our
common stock outstanding on the date of the ELOC Purchase Agreement (the &ldquo;Exchange Cap&rdquo;), unless we first obtain stockholder
approval to issue shares in excess of such amount under the ELOC Purchase Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Terms of the Offering</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Selling Stockholder and any of their pledgees, assignees and successors-in-interest
will determine when and how they sell the shares offered in this prospectus and may, from time to time, sell any or all of their shares
of common stock covered hereby on Nasdaq or any other stock exchange, market or trading facility on which the shares are traded or in
privately negotiated transactions. These sales may be at fixed or negotiated prices. For more information, see the section of this prospectus
entitled &ldquo;<I>Plan of Distribution</I>&rdquo; beginning on page 16.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Use of Proceeds</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">The Selling Stockholder will receive all
of the proceeds from the sale of the shares of common stock offered for sale by it under this prospectus. We will not receive proceeds
from the sale of the shares of common stock by the Selling Stockholder.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">We may receive up to $36,000,000 in aggregate
gross proceeds under the ELOC Purchase Agreement in connection with sales of our shares of common stock to the Selling Stockholder that
we may, in our discretion, elect to make, from time to time pursuant to the ELOC Purchase Agreement after the date of this prospectus.
We intend to use the proceeds from the sale of our shares of common stock to the Selling Stockholder for general corporate purposes.
Our management will have broad discretion over the use of proceeds from the sale of our shares of common stock under the ELOC Purchase
Agreement.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">For more information, see the section of this
    prospectus entitled &ldquo;<I>Use of Proceeds</I>&rdquo; beginning on page 10.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Risk Factors</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You should read the &ldquo;<I>Risk Factors</I>&rdquo; section of this prospectus beginning on page 9 of this prospectus and under similar headings in the documents incorporated by reference into this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt"><B>Nasdaq Capital Market Symbol</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">SNYR</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt"><B>Transfer Agent and Registrar</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">VStock Transfer, LLC</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of May 14, 2026, 15,079,956&nbsp;shares
of our common stock were issued and 14,899,883&nbsp;shares were outstanding. Unless we indicate otherwise or the context otherwise requires,
all information in this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">does not reflect 1,540,000&nbsp;Warrant Shares issuable upon the exercise
of the Warrant at an exercise price of $0.01 per share;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">does not reflect 1,200,000&nbsp;shares of common stock issuable upon
the exercise of outstanding options at a weighted average exercise price of $2.38 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">does not reflect 2,252,102&nbsp;shares of common stock reserved for
future issuance pursuant to the Synergy CHC Corp. 2024 Equity Incentive Plan (the &ldquo;2024 Equity Incentive Plan&rdquo;); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">does not reflect 3,156,000&nbsp;shares of common stock issuable upon
the exercise of outstanding warrants at a weighted average exercise price of $0.43 per share.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Investing in our securities
involves risk. Before making an investment decision, you should carefully consider the following discussion of risks and uncertainties
affecting us and our securities, together with all of the other information included or incorporated by reference in this prospectus,
including the consolidated financial statements and the accompanying notes and matters addressed in the section titled &ldquo;<I>Cautionary
Note&nbsp;Regarding Forward-Looking Statements</I>,&rdquo; in evaluating an investment in our securities. You should also consider the
risks, uncertainties and assumptions discussed under Item&nbsp;1A, &ldquo;<I>Risk Factors</I>,&rdquo; in our most recent Annual Report
on Form&nbsp;10-K, which is incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other
reports we file with the SEC in the future. The following risk factors apply to the business and operations of the Company and its consolidated
subsidiaries. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with
other events or circumstances, may have an adverse effect on our business, cash flows, financial condition and results of operations.
The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. The risks
and uncertainties we discuss in this prospectus and under similar headings in the documents incorporated by reference into this prospectus
are those that we currently believe may materially affect our company. Additional risks and uncertainties not presently known to us or
that we currently deem immaterial also may materially and adversely affect our business, financial condition and results of operations.
Past performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results
or trends in future periods. See also the section of this prospectus titled &ldquo;<I>Where You Can Find More Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The risk factors set forth
below supplement the risk factors previously disclosed and should be read together with the risk factors incorporated by reference herein
and any additional risk factors that we may include in subsequent periodic filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering and Our Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>It is not possible to predict the actual
number of shares we will issue to the Selling Stockholder.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The purchase price to be paid
by the Selling Stockholder for the ELOC Shares will be the lesser of (i) ninety-five percent (95%) of the average of the three lowest
traded prices of the Company&rsquo;s common stock during the five trading days immediately preceding the date of the Put Notice (as defined
in the ELOC Purchase Agreement) and (ii) ninety-five percent (95%) of the lowest closing price of the Company&rsquo;s common stock on
any trading day during the three trading days immediately following the Clearing Date (as defined in the ELOC Purchase Agreement). The
Company shall, in its sole discretion, select the amount of ELOC Shares requested by the Company in each Put Notice. However, such amount
must not be less than $25,000 and may not exceed the lesser of (i) $2,500,000 or (ii) 200% of the average daily trading volume of the
common stock during the three trading days immediately before the date of the Put Notice. Accordingly, the number of ELOC Shares issuable
pursuant to the ELOC Purchase Agreement cannot be determined at this time and may change over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investors who buy shares at different times
will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The Selling Stockholder will
purchase shares in this offering at different times and, therefore, will likely pay different prices. As such, investors may experience
different levels of dilution and different outcomes in their investment results. The Selling Stockholder may sell such shares at different
times and at different prices. Investors may experience a decline in the value of the shares they purchase from the Selling Stockholder
in this offering as a result of sales made by us in future transactions to the Selling Stockholder at prices lower than the prices they
paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The issuance of common stock to the Selling
Stockholder may cause substantial dilution to our existing stockholders and the sale of such shares acquired by the Selling Stockholder
could cause the price of our common stock to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are registering for resale
by the Selling Stockholder up to 101,710,000 shares of common stock, comprised of (i) 100,000,000 ELOC Shares, (ii) 1,540,000 Warrant
Shares and 170,000 Existing Shares. The number of shares of our common stock ultimately offered for resale by the Selling Stockholder
under this prospectus is dependent upon the number of ELOC Shares issued. Depending on a variety of factors, including market liquidity
of our common stock, the issuance of shares to the Selling Stockholder may cause the trading price of our common stock to decline.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have not historically paid or declared
any dividends on our common stock and do not expect to pay or declare cash dividends in the future on a regular basis, if at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We have not historically paid
or declared any dividends on our common stock. Any future dividends on our common stock will be declared at the discretion of our board
of directors and will depend, among other things, on our earnings, our financial requirements for future operations and growth, and other
facts as we may then deem appropriate. As such, the return on your investment, if any, has historically been dependent solely on an increase,
if any, in the market value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The Selling Stockholder will
receive all of the proceeds of the sale of shares of common stock offered from time to time pursuant to this prospectus. Accordingly,
we will not receive any proceeds from the sale of shares of common stock that may be sold from time to time pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We may receive up to $36,000,000
in aggregate gross proceeds under the ELOC Purchase Agreement in connection with sales of our shares of common stock to the Selling Stockholder
that we may, in our discretion, elect to make, from time to time pursuant to the ELOC Purchase Agreement after the date of this prospectus.
As of the date of this prospectus, we cannot currently allocate specific percentages of the proceeds that we may obtain under the ELOC
Purchase Agreement to particular uses and we cannot estimate the amount of proceeds that we will actually spend as opposed to retaining
for working capital purposes. Therefore, we currently intend to use the net proceeds received under the ELOC Purchase Agreement for working
capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The amounts and timing of our
actual expenditures will depend upon numerous factors, including our sales and marketing efforts, demand for our products, our operating
costs and the other factors described under and incorporated by reference in &ldquo;<I>Risk Factors</I>&rdquo; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our expected use of net proceeds
from the sale of our shares of common stock under the ELOC Purchase Agreement represents our current intentions based upon our present
plans and business condition, which could change in the future as our plans and business conditions evolve. Circumstances that may give
rise to a change in the use of proceeds and the alternate purposes for which the proceeds may be used include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The existence of other opportunities or the need to take
advantage of changes in timing of our existing activities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The need or desire on our part to accelerate, increase or
eliminate existing initiatives due to, among other things, changing market conditions and competitive developments; and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">If strategic opportunities present themselves (including
acquisitions, joint ventures, licensing and other similar transactions).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">As a result, we cannot predict
with any certainty our use of the net proceeds from this offering. Our management will retain broad discretion over the allocation of
the net proceeds from this offering. Accordingly, we will have discretion in the application of the net proceeds, and investors will be
relying on our judgment regarding the application of the proceeds we may receive under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The Selling Stockholder may
from time to time offer and sell any or all of the shares of common stock set forth below pursuant to this prospectus. When we refer to
the Selling Stockholder in this prospectus, we refer to the entity listed in the table below, and the pledgees, donees, transferees, assignees,
successors and other permitted transferees that hold the Selling Stockholder&rsquo;s interest in the shares of common stock after the
date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The following table sets forth
certain information provided by or on behalf of the Selling Stockholder concerning the shares of common stock that may be offered from
time to time by the Selling Stockholder pursuant to this prospectus. The Selling Stockholder identified below may have sold, transferred
or otherwise disposed of all or a portion of their shares of common stock or other Company securities after the date on which they provided
us with information regarding such securities. Moreover, the shares of common stock identified below include only the shares being registered
for resale and may not incorporate all shares of common stock or other securities of the Company deemed to be beneficially held by the
Selling Stockholder. The number of shares of common stock beneficially owned by the Selling Stockholder is determined under rules promulgated
by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Any changed or new information
given to us by the Selling Stockholder, including regarding the identity of, and the securities held by, the Selling Stockholder, will
be set forth in a prospectus supplement or amendments to the Registration Statement, if and when necessary. The Selling Stockholder may
sell all, some or none of the shares of common stock in this offering. See the section of this prospectus entitled &ldquo;<I>Plan of Distribution</I>&rdquo;
for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Other than as described below
or elsewhere in this prospectus, the Selling Stockholder does not have any material relationship with us or any of our predecessors or
affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name and address of Selling Stockholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Shares<BR> Owned<BR> Prior to<BR> the<BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum<BR> Number<BR> of Shares to<BR> be Sold<BR> Pursuant<BR> to this<BR> Prospectus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of<BR> Shares<BR> Owned<BR> After<BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent of<BR> Shares<BR> Owned<BR> After<BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hudson Global Ventures, LLC<SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">170,000</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">101,710,000</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&mdash;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&mdash;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Assumes that the Selling Stockholder will sell all of the shares offered by them under this prospectus.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The principal business address for the Selling Stockholder is 1 Linden Place, Suite 210, Great Neck, NY 11021. Seth Ahdoot and Soheil Ahdoot have voting and dispositive power over the shares owned by the Selling Stockholder.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>THE ELOC PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">On May 8, 2026, we entered
into the ELOC Purchase Agreement with the Selling Stockholder, pursuant to which we have the right, but not the obligation, to direct
the Selling Stockholder to purchase up to $36,000,000 in ELOC Shares upon satisfaction of certain terms and conditions contained in the
ELOC Purchase Agreement. Such sales of our common stock, if any, will be subject to certain limitations, and may occur from time to time
at our sole discretion over the approximately 24-month period commencing on the date of execution of the ELOC Purchase Agreement, provided
that the Registration Statement, and any other registration statement the Company may file from time to time covering the resale by the
Selling Stockholder of ELOC Shares or Warrant Shares, is declared effective by the SEC and remains effective, and the other conditions
set forth in the ELOC Purchase Agreement are satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The Selling Stockholder has
no right to require any sales by us, but the Selling Stockholder is obligated to make purchases at our direction subject to certain conditions.
The purchase price per share is determined pursuant to the formula set forth in the ELOC Purchase Agreement and is based on discounted
market prices of our common stock. Actual sales of ELOC Shares to the Selling Stockholder from time to time will depend on a variety of
factors, including, among others, market conditions, the trading price of our common stock and determinations by us as to the appropriate
sources of funding for us and our operations. The net proceeds that we may receive under the ELOC Purchase Agreement, if any, cannot be
determined at this time, since it will depend on the frequency and prices at which we sell ELOC Shares to Selling Stockholder, our ability
to meet the conditions of the ELOC Purchase Agreement, and the other limitations, terms and conditions of the ELOC Purchase Agreement
and any impacts of the Beneficial Ownership Limitation (defined herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The ELOC Purchase Agreement
contains customary representations, warranties, conditions and indemnification obligations of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purchase of ELOC Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Under the ELOC Purchase Agreement,
after the satisfaction of certain conditions, we have the right to deliver a Put Notice to the Selling Stockholder that directs the Selling
Stockholder to purchase an amount of ELOC Shares in an amount totaling at least $25,000 but not exceeding the lesser of (i) $2,500,000
or (ii) 200% of the average daily trading volume of the common stock during the three trading days immediately before the date of the
Put Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The purchase price to be paid
by the Selling Stockholder for the ELOC Shares included in a Put Notice will be the lesser of (i) ninety-five percent (95%) of the average
of the three lowest traded prices of the Company&rsquo;s common stock during the five trading days immediately preceding the date of the
Put Notice (as defined in the ELOC Purchase Agreement) and (ii) ninety-five percent (95%) of the lowest closing price of the Company&rsquo;s
common stock on any trading day during the three trading days immediately following the Clearing Date (as defined in the ELOC Purchase
Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consideration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">As consideration for the Selling
Stockholder&rsquo;s execution and delivery of the ELOC Purchase Agreement, we agreed to issue to the Selling Stockholder the Warrant to
purchase 1,540,000 shares of common stock as a commitment fee. We are registering all 1,540,000 Warrant Shares under the Registration
Statement. We also agreed to pay $20,000.00 to the Selling Stockholder&rsquo;s legal counsel for the Selling Stockholder&rsquo;s expenses
relating to the preparation of the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>C</B></FONT><B>onditions
to Delivery of Advance Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our ability to deliver Put
Notices under the ELOC Purchase Agreement is subject to the satisfaction of certain conditions, including, among other things, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Registration Statement, and any amendment or supplement thereto, must remain effective for the resale by the Selling Stockholder of the ELOC Shares and Warrant Shares at prevailing market prices and (i) neither the Company nor the Selling Stockholder shall have received notice that the SEC has issued or intends to issue a stop order with respect to the Registration Statement or that the SEC otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, or intends or has threatened to do so and (ii) there must not be any other suspension of the use of, or withdrawal of the effectiveness of, the Registration Statement or related prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The representations and warranties of the Company must be true and correct in all material respects as of the date of the ELOC Purchase Agreement and as of the date of each closing on ELOC Shares under the ELOC Purchase Agreement (except for representations and warranties specifically made as of a particular date).</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the ELOC Purchase Agreement to be performed, satisfied or complied with by the Company, including but not limited to the delivery of the ELOC Shares in accordance with the ELOC Purchase Agreement.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">There must not be a statute,
rule, regulation, executive order, decree, ruling or injunction that has been enacted, entered, promulgated or adopted by any court or
governmental authority of competent jurisdiction that prohibits or directly and materially adversely affects any of the transactions
contemplated by the ELOC Purchase Agreement, or any proceeding that may have the effect of prohibiting or materially adversely affecting
any of the transactions contemplated by the ELOC Purchase Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">There must not be an event
that has had or is reasonably likely to have a material adverse effect on the Company since the date the Company filed its most recent
report with the SEC.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Trading of the common stock
must not have been suspended by the SEC, Nasdaq, or FINRA, or otherwise halted for any reason, and the common stock must not have been
delisted from Nasdaq.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The number of ELOC Shares to
be purchased by the Selling Stockholder, combined with the number of shares of common stock then owned by the Selling Stockholder, must
not exceed the Beneficial Ownership Limitation (defined herein).</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The common stock must not be
deemed a &ldquo;penny stock&rdquo; as defined in SEC Rule 240.3a51-1.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must not know of
any event more likely than not to have the effect of causing the Registration Statement to be suspended or otherwise ineffective.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The issuance of the ELOC Shares
must not violate the stockholder approval requirements of Nasdaq.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On the date of delivery of
each Put Notice, the Selling Stockholder must have received a closing certificate executed by an executive officer of the Company stating
that all conditions to such closing have been satisfied as of the date of the certificate.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The common stock must be eligible
for Deposit Withdrawal at Custodian and not subject to a &ldquo;DTC chill.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All reports, schedules, registrations,
forms, statements, information and other documents required to have been filed by the Company with the SEC pursuant to the reporting
requirements of the Exchange Act must have been filed with the SEC within the applicable time periods prescribed for such filings under
the Exchange Act.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must have reserved
the Required Minimum (as defined in the ELOC Purchase Agreement) for the Selling Stockholder&rsquo;s benefit under the ELOC Purchase
Agreement and the Company must have satisfied the reserve requirements with respect to all other contracts between the Company and the
Selling Stockholder.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The lowest traded price of
the common stock in the ten (10) trading days immediately preceding the respective Put Date must exceed $0.01 per share.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Bankruptcy, insolvency, reorganization
or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief
of debtors must not have been instituted by or against the Company or any subsidiary of the Company, and the Company must not have knowledge
of any event more likely than not to have the effect of causing such a proceeding to arise.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitation on Sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">At any given time of any sale
by us to the Selling Stockholder, we may not sell, and the Selling Stockholder may not purchase, ELOC Shares that would result in the
Selling Stockholder beneficially owning more than the 4.99% of the number of shares of common stock outstanding immediately after giving
effect to the issuance of shares of common stock issuable pursuant to a Put Notice (the &ldquo;Beneficial Ownership Limitation&rdquo;).
Additionally, the Company must obtain stockholder approval to issue an aggregate number of shares of common stock to the Selling Stockholder
under the ELOC Purchase Agreement, in excess of the Exchange Cap prior to delivering any Put Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Commitment Fee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">As consideration for the Selling
Stockholder&rsquo;s execution and delivery of the ELOC Purchase Agreement, the Company issued to the Selling Stockholder the Warrant for
the purchase of 1,540,000 shares of the common stock at an exercise price of $0.01 per share, subject to adjustment. Under the Warrant,
the Selling Stockholder may exercise the Warrant during the period commencing on May 8, 2026 and ending on 5:00 p.m. eastern standard
time on the date that is five (5) years after May 8, 2026. In addition, the Company will pay up to $20,000.00 to the Selling Stockholder&rsquo;s
legal counsel for the Selling Stockholder&rsquo;s expenses relating to the preparation of the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">In connection with our entry
into the ELOC Purchase Agreement we also entered into a registration rights agreement with the Selling Stockholder (the &ldquo;Registration
Rights Agreement&rdquo;).&nbsp;Under the Registration Rights Agreement, we are obligated to file with the SEC a registration statement
for the resale by the Selling Stockholder of the ELOC Shares and the Warrant Shares within thirty (30) days of the execution of the ELOC
Purchase Agreement, and to file one or more additional registration statements if necessary. The Registration Statement is being filed
in order to satisfy our obligations under the ELOC Purchase Agreement and the Registration Rights Agreement related to registering for
resale the ELOC Shares and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Once this Registration Statement
is declared effective by the SEC, if it becomes necessary for us to issue and sell to the Selling Stockholder a greater number of shares
of our common stock than are registered for resale under this Registration Statement, we will be required to file one or more additional
registration statements with the SEC to register the resale of such additional shares under the Securities Act. Each such registration
statement would need to be declared effective by the SEC before we may elect to sell any additional shares of our common stock to the
Selling Stockholder under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Termination of the ELOC Purchase Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Unless earlier terminated as
provided in the ELOC Purchase Agreement, the ELOC Purchase Agreement will terminate automatically at the end of the Commitment Period.
The &ldquo;Commitment Period&rdquo; commences on May 8, 2026 and ends on the earliest to occur of: (i) the date on which the Selling Stockholder
has purchased ELOC Shares equal to the $36,000,000 maximum commitment amount, (ii) twenty-four (24) months after May 8, 2026, (iii) written
notice of termination by the Company to the Selling Stockholder (subject to certain limitations if the Selling Stockholder then holds
ELOC Shares), (iv) this Registration Statement is no longer effective after the initial effective date of this Registration Statement,
and (v) the occurrence of certain bankruptcy or insolvency-related events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitation on Equity Line of Credit and Variable
Rate Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Pursuant to the ELOC Purchase
Agreement, until the later of (i) twenty-four (24) months from May 8, 2026 or (ii) the date the ELOC Purchase Agreement is no longer in
effect, the Company agreed that it will not, without the prior written consent of the Selling Stockholder, enter into any other &ldquo;Equity
Line of Credit&rdquo; (which is generally defined as any transaction involving a written agreement between the Company and an investor
or underwriter whereby the Company has the right to &ldquo;put&rdquo; its securities to such investor or underwriter over an agreed period
of time and at an agreed price or price formula).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">So long as the ELOC Purchase
Agreement remains in effect, the Company also agreed that it will not, without the prior written consent of the Selling Stockholder, enter
into any &ldquo;Variable Rate Transaction&rdquo; (as defined in the ELOC Purchase Agreement) with any other party, unless the Company
first provides the Selling Stockholder with (i) a term sheet detailing the proposed Variable Rate Transaction (including the dollar amount,
price and other terms upon which the securities are to be issued, sold or exchanged) and (ii) a three (3) trading day period for the Selling
Stockholder to elect to consummate such Variable Rate Transaction with the Company. If the Selling Stockholder elects not to consummate
such Variable Rate Transaction with the Company, then the references to &ldquo;95%&rdquo; in the definitions of both the Initial Purchase
Price and the Market Price under the ELOC Purchase Agreement are automatically amended to &ldquo;90%&rdquo;. The ELOC Purchase Agreement
also provides that an Equity Line of Credit and an at-the-market offering under the Company&rsquo;s existing sales agreement are not deemed
to be Variable Rate Transactions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dilutive Effect</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">All shares of common stock
registered in this offering which have been or may be issued or sold by us to the Selling Stockholder under the ELOC Purchase Agreement
are expected to be freely tradable. It is anticipated that the shares of common stock registered in this offering will be sold over a
period starting on the date that the Registration Statement is declared effective. The sale by the Selling Stockholder of a significant
amount of common stock registered in this offering could cause the market price of our common stock to decline and to be highly volatile.
Sales of ELOC Shares to the Selling Stockholder, if any, will depend upon market conditions and other factors to be determined by us.
We may ultimately decide to sell to the Selling Stockholder all, some or none of the ELOC Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The Selling Stockholder may
resell all, some or none of the shares of common stock held by it at any time, or from time to time, in its discretion. Therefore, sales
to the Selling Stockholder by us under the ELOC Purchase Agreement may result in substantial dilution to the interests of other holders
of our common stock. In addition, if we sell a substantial number of ELOC Shares to the Selling Stockholder, or if investors expect that
we will do so, the actual sales of ELOC Shares or the mere existence of our arrangement with the Selling Stockholder may make it more
difficult for us to sell securities in the future at a time and at a price that we might otherwise wish to effect such sales. However,
we have the right to control the timing and amount of any sales to the Selling Stockholder and we are not obligated to submit any Put
Notices under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The following table sets forth
the amount of gross proceeds we would receive from the Selling Stockholder from the sale of all ELOC Shares that could be issued to the
Selling Stockholder under the ELOC Purchase Agreement at varying purchase prices, without giving effect to the Beneficial Ownership Limitation
or the Exchange Cap. The presentation of this information is for illustrative purposes only. As noted above, we are not obligated to submit
any Put Notices under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Assumed<BR>
 Average<BR>
 Purchase<BR>
 Price&nbsp;Per<BR>
 Share<SUP>(1)</SUP> </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Shares of<BR>
 Registered Common Stock to<BR>
 be&nbsp;Issued if Full Purchase,<BR>
 Without Giving Effect to the<BR>
 Beneficial Ownership<BR>
 Limitation<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage of Outstanding<BR>
 Common Stock After Giving<BR>
 Effect to the Issuance to the Selling<BR>
 Stockholder, Without Giving<BR>
 Effect to the Beneficial Ownership<BR>
 Limitation<SUP>(3)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proceeds from the Sale
    of<BR>
 Common Stock to the<BR> Selling Stockholder<BR> Under the ELOC<BR> Purchase Agreement</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 22%; text-align: right"><FONT STYLE="font-size: 10pt">0.25</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 22%; text-align: right"><FONT STYLE="font-size: 10pt">144,000,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 23%; text-align: right"><FONT STYLE="font-size: 10pt">90.62</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 22%; text-align: right"><FONT STYLE="font-size: 10pt">36,000,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">0.27</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">133,333,333</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">89.95</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">36,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">0.29</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><SUP>(4)</SUP></FONT>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">124,137,931</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">89.28</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">36,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">0.31</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">116,129,032</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">88.63</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">36,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">0.33</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">109,090,909</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">87.98</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">36,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">For the avoidance of any doubt,
this price reflects the purchase price after calculation (i.e. after discounts to the market price of our shares) in accordance with
the terms of the ELOC Purchase Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents the number of Warrant
Shares issued and the number of ELOC Shares that could potentially be issued to the Selling Stockholder, in the aggregate and rounded
up, based on the applicable assumed purchase price per share, without giving effect to the Beneficial Ownership Limitation or the Exchange
Cap.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The denominator is based on
14,899,883 shares of our common stock outstanding as of May 14, 2026, adjusted to include the issuance of the number of shares of common
stock set forth in the adjacent column which we would have issued to the Selling Stockholder based on the applicable assumed purchase
price per share.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents the last reported
sales price of our common stock on May 13, 2026, as reported by Nasdaq, less a five percent (5%) discount and rounded up to the nearest
penny.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The ELOC Shares and Warrant
Shares will be offered and sold to the Selling Stockholder in reliance upon the exemption from registration provided by Section 4(a)(2)
of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The foregoing summary of the
ELOC Purchase Agreement is qualified in its entirety by reference to the full text of the ELOC Purchase Agreement, which is incorporated
by reference as Exhibit 10.25 to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The Selling Stockholder, including
its donees, pledgees, transferees or other successors-in-interest selling shares or interests in shares received after the date of this
prospectus from the Selling Stockholder as a gift, pledge, partnership distribution or other transfer, may from time to time sell, transfer
or otherwise dispose of any or all of the shares of common stock registered under the Registration Statement on any stock exchange, market
or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing
market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale,
or at negotiated prices. The Selling Stockholder may use any one or more of the following methods when selling the shares, unless it is
contractually bound not to use such methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary brokerage transactions
and transactions in which the broker-dealer solicits purchasers;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">block trades in which the broker-dealer
will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases by a broker-dealer
as principal and resale by the broker-dealer for its account;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exchange distribution in
accordance with the rules of the applicable exchange;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">privately negotiated transactions;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">settlement of short sales;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in transactions through broker-dealers
that agree with the Selling Stockholder to sell a specified number of shares at a stipulated price per security;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">through the writing or settlement
of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a combination of any such methods
of sale; or</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other method permitted
pursuant to applicable law.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The Selling Stockholder may
also sell the shares under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Broker-dealers engaged by the
Selling Stockholder may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of the shares, from the purchaser) in amounts to
be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance
with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The Selling Stockholder is,
and any broker-dealer or agent that is involved in selling the shares may be deemed to be, an &ldquo;underwriter&rdquo; within the meaning
of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.
The Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly,
with any person to distribute the shares of common stock registered under the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We are required to pay certain
fees and expenses incurred by us incident to the registration of these shares of common stock. We have agreed to indemnify the Selling
Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We have also agreed to keep
this prospectus effective until all of the shares of common stock have been sold pursuant to this prospectus. The shares of common stock
will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in
certain states, the shares covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state
or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Compliance with the Exchange Act, including
Regulation M</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the shares of common stock may not simultaneously engage
in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to
the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act
and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock
by the Selling Stockholder or any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><I>The following descriptions
are summaries of the material terms of our certificate of incorporation and amended and restated bylaws, to which you should refer. Reference
is made to the more detailed provisions of, and the descriptions are qualified in their entirety by reference to, the certificate of incorporation
and amended and restated bylaws, which are filed with the SEC as exhibits to the registration statement of which this prospectus is a
part, and applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our authorized capital stock consists of 300,000,000&nbsp;shares of
common stock, par value $0.00001 per share and 1,000,000&nbsp;shares of undesignated preferred stock, $0.00001 par value. As of May 14,
2026, there were 15,079,956&nbsp;shares of common stock issued and 14,899,883&nbsp;shares of common stock outstanding, held by approximately
68&nbsp;stockholders of record. As of the date of this prospectus, no shares of preferred stock were issued or outstanding. Upon completion
of this offering, there will be 116,439,883&nbsp;shares of common stock outstanding, assuming the sale of all of the ELOC Shares and Warrant
Shares registered under the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividend Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The holders of outstanding
shares of our common stock are entitled to receive dividends out of funds legally available at the times and in the amounts that our Board
of Directors may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Each holder of our common stock
is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Cumulative voting for
the election of directors is not provided for in our articles of incorporation, which means that the holders of a majority of our shares
of common stock voted can elect all of the directors then standing for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Preemptive or Similar Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our common stock is not entitled
to preemptive rights and is not subject to conversion or redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Upon our liquidation, dissolution,
or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our
common stock outstanding at that time after payment of other claims of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our articles of incorporation
provide that our Board of Directors is authorized to issue shares of preferred stock from time to time in one or more series. Our Board
of Directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional
or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our Board
of Directors is able to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect
the voting power and other rights of the holders of the common stock and could have anti-takeover effects. The ability of our Board of
Directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of
control of us or the removal of existing management. We have no preferred stock outstanding at the date hereof. Although we do not currently
intend to issue any shares of preferred stock, we cannot assure you that we will not do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover&nbsp;Effects of Certain Provisions
of Nevada Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><I>Effect of Nevada</I>&nbsp;<I>Anti</I>-<I>takeover</I>&nbsp;<I>Statute</I>.
We are subject to Section&nbsp;78.438 of the Nevada Revised Statutes, an anti-takeover&nbsp;law. In general, Section&nbsp;78.438 prohibits
a Nevada corporation from engaging in any business combination with any interested stockholder for a period of two&nbsp;years following
the date that the stockholder became an interested stockholder, unless prior to that date, the board of directors of the corporation approved
either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder, or if after the
date that the stockholder becomes an interested stockholder the business combination is approved by the board of directors and by 60%
of the voting power of all disinterested stockholders at either an annual or special meeting of the stockholders of the corporation. Section&nbsp;78.439
provides that business combinations after the two-year&nbsp;period following the date that the stockholder becomes an interested stockholder
may also be prohibited unless either approved by the corporation&rsquo;s directors before the stock acquisition, or by a majority of the
disinterested stockholders or unless the price and terms of the transaction meet other criteria set forth in the statute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">Section&nbsp;78.416 defines &ldquo;business
combination&rdquo; to include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any merger or consolidation involving the corporation and the
interested stockholder or any other corporation which is an affiliate or associate of the interested stockholder;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any sale, transfer, pledge or other disposition of the assets
of the corporation involving the interested stockholder or any affiliate or associate of the interested stockholder if the assets transferred
have a market value equal to 5% or more of all of the assets of the corporation or 5% or more of the value of the outstanding shares
of the corporation or represent 10% or more of the earning power of the corporation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">subject to certain exceptions, any transaction that results
in the issuance or transfer by the corporation of any stock of the corporation to an interested stockholder, with a market value of 5%
or more of the value of the outstanding shares of the corporation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the adoption of a plan of liquidation proposed by or under any
arrangement with the interested stockholder or any affiliate or associate of the interested stockholder;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any transaction involving the corporation that has the effect
of increasing the proportionate share of the stock of any class or series of voting shares of securities convertible into voting shares
of the corporation beneficially owned by the interested stockholder or any affiliate or associate of the interested stockholder; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the receipt by the interested stockholder or any affiliate or
associate of the interested stockholder of the benefit, except proportionately as a stockholder of the corporation, of any loans, advances,
guarantees, pledges or other financial benefits provided by or through the corporation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">In general, Section&nbsp;78.423
defines an interested stockholder as any entity or person beneficially owning, directly or indirectly, 10% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with or controlling or controlled by any of these entities or persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><I>Control Share Acquisitions.&nbsp;&nbsp;&nbsp;&nbsp;</I>Sections
78.378 through 78.3793 of the Nevada Revised Statutes limit the voting rights of certain acquired shares in a corporation. The provisions
apply to any acquisition of outstanding voting securities of a Nevada corporation that has 200 or more stockholders, at least 100 of which
are Nevada residents, and conducts business in Nevada (an &ldquo;issuing corporation&rdquo;) resulting in ownership of one of the following
categories of an issuing corporation&rsquo;s then outstanding voting securities: (i)&nbsp;twenty percent or more but less than thirty-three&nbsp;percent;
(ii)&nbsp;thirty-three&nbsp;percent or more but less than fifty percent; or (iii)&nbsp;fifty percent or more. The securities acquired
in such acquisition are denied voting rights unless a majority of the security holders approve the granting of such voting rights. Unless
an issuing corporation&rsquo;s articles of incorporation or bylaws then in effect provide otherwise: (i)&nbsp;voting securities acquired
are also redeemable in part or in whole by an issuing corporation at the average price paid for the securities within 30&nbsp;days if
the acquiring person has not given a timely information statement to an issuing corporation or if the stockholders vote not to grant voting
rights to the acquiring person&rsquo;s securities, and (ii)&nbsp;if outstanding securities and the security holders grant voting rights
to such acquiring person, then any security holder who voted against granting voting rights to the acquiring person may demand the purchase
from an issuing corporation, for fair value, all or any portion of his securities. These provisions do not apply to acquisitions made
pursuant to the laws of descent and distribution, the enforcement of a judgment, or the satisfaction of a security interest, or made in
connection with certain mergers or reorganizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Neither our articles of incorporation,
nor our amended and restated bylaws, prevent us from indemnifying our officers, directors and agents to the extent permitted under the
Nevada Revised Statutes (&ldquo;NRS&rdquo;). NRS Section&nbsp;78.7502, provides that a corporation may indemnify any director, officer,
employee or agent of a corporation against expenses, including fees, actually and reasonably incurred by him in connection with any defense
to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of
any action, suit or proceeding referred to Section&nbsp;78.7502(1)&nbsp;or 78.7502(2), or in defense of any claim, issue or matter therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">NRS 78.7502(1)&nbsp;provides
that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation,
by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
against expenses, including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by
him in connection with the action, suit or proceeding if he: (a)&nbsp;is not liable pursuant to NRS 78.138; or (b)&nbsp;acted in good
faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect
to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">NRS Section&nbsp;78.7502(2)&nbsp;provides
that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement
and attorneys&rsquo; fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if
he: (a)&nbsp;is not liable pursuant to NRS 78.138; or (b)&nbsp;acted in good faith and in a manner which he reasonably believed to be
in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which
such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the
corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or
suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case,
the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">NRS Section&nbsp;78.747 provides
that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability
of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine
the question of whether a director or officer acts as the alter ego of a corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our amended and restated bylaws
provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions
of the NRS, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth
in any stockholders&rsquo; or directors&rsquo; resolution or by contract. Any repeal or modification of these provisions approved by our
stockholders will be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers
existing as of the time of such repeal or modification. We are also permitted to apply for insurance on behalf of any director, officer,
employee or other agent for liability arising out of his actions, whether or not the NRS would permit indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We have entered into agreements
with our officers and directors that provide contractual indemnification in addition to the indemnification provided for in our articles
of incorporation and amended and restated bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We do not currently carry directors&rsquo;
and officers&rsquo; insurance. However, we may in the future purchase a policy of directors&rsquo; and officers&rsquo; liability insurance
that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures
us against our obligations to indemnify our officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">These provisions may discourage
stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect
of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise
benefit us and our stockholders. Furthermore, a stockholder&rsquo;s investment may be adversely affected to the extent we pay the costs
of settlement and damage awards against officers and directors pursuant to these indemnification provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We believe that these provisions
and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Shares of our common stock
are listed on the Nasdaq Capital Market under the symbol &ldquo;SNYR&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The transfer agent and registrar
for our common stock is VStock Transfer LLC, 18 Lafayette Place, Woodmere, New&nbsp;York 11598.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The validity of the shares
of common stock offered hereby will be passed upon for us by Nelson Mullins Riley&nbsp;&amp; Scarborough LLP, Raleigh, North Carolina.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The consolidated financial
statements of Synergy CHC Corp. as of December&nbsp;31, 2025 and 2024 and for the&nbsp;years then ended included in this prospectus have
been so included in reliance on the reports of RBSM LLP, an independent registered public accounting firm, which are included herein,
given on the authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">This prospectus is part of
a registration statement that we filed with the SEC and does not contain all of the information set forth in the registration statement
and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this
prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You
should rely only on the information contained in this prospectus. We have not authorized anyone else to provide you with different information.
We are not making an offer of these securities in any jurisdiction where the offer is not permitted. You should assume that the information
contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus
or any sale of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We file annual, quarterly and
current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public from commercial document
retrieval services and over the Internet at the SEC&rsquo;s website at <I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We maintain a website at <I>www.synergychc.com</I>.
You may access our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports
filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably
practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed
through, our website is not incorporated by reference into, and is not part of, this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The SEC&rsquo;s rules allow
us to &ldquo;incorporate by reference&rdquo; information into this prospectus, which means that we can disclose important information
to you by referring you to another document filed separately with the SEC.&nbsp;The information incorporated by reference is deemed to
be part of this prospectus. Any statement contained in this prospectus or a previously filed document incorporated by reference will be
deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies
or replaces that statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Annual Report on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1562733/000121390026037883/ea0283513-10k_synergy.htm">Form&nbsp;10-K</A>&nbsp;for the year ended
December&nbsp;31, 2025 filed on April 1, 2026;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Those portions of our Definitive Proxy Statement on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1562733/000121390026050246/ea0286780-04.htm">Schedule&nbsp;14A</A>
for our 2026 Annual Meeting of Stockholders filed with the SEC on April&nbsp;30, 2026 that are incorporated by reference into our Annual
Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1562733/000121390026037883/ea0283513-10k_synergy.htm">Form&nbsp;10-K</A> for the year ended December&nbsp;31, 2025;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Quarterly Report on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1562733/000121390026056237/ea0290227-10q_synergy.htm">Form&nbsp;10-Q</A>&nbsp;for the three months
ended March&nbsp;31, 2026 filed on May 14, 2026;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Current Report on&nbsp;Form&nbsp;8-K&nbsp;(excluding any reports
or portions thereof that are deemed to be furnished and not filed) filed on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1562733/000121390026023195/ea0279861-8k_synergy.htm">March 3, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1562733/000121390026034072/ea0283223-8k_synergy.htm">March 25, 2026</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1562733/000121390026054186/ea0289929-8k_synergy.htm">May 11, 2026</A>; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our registration statement on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024089069/ea0217828-8a12b_synergy.htm">Form&nbsp;8-A</A>&nbsp;filed
on October&nbsp;21, 2024.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We also incorporate by reference
any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange&nbsp;Act after (i)&nbsp;the date of
this registration statement and prior to effectiveness of this registration statement and (ii)&nbsp;the date of this prospectus and before
the termination of the offering of the securities included in this prospectus, however, we will not incorporate by reference any document
or portions thereof that are not deemed &ldquo;filed&rdquo; with the SEC, or any information furnished pursuant to Items 2.02 or 7.01
of Form&nbsp;8-K or related exhibits furnished pursuant to Item&nbsp;9.01 of Current Reports on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We will provide, without charge,
to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon such person&rsquo;s written or oral
request, a copy of any and all of the information incorporated by reference in this prospectus. You may request a free copy of any of
the documents incorporated by reference in this prospectus by writing or telephoning us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Synergy CHC Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">770 Roosevelt Trail STE 8 #1016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N. Windham, Maine 04062</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(207) 321-2350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Exhibits to the filings will
not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>101,710,000 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="ea029095401_img5.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synergy CHC Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2026</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;II &mdash; INFORMATION NOT REQUIRED
IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B>Item&nbsp;13.
Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The following table sets forth all costs and expenses, other than underwriting
discounts and commissions, paid or payable by us in connection with the sale of the common stock being registered. All amounts shown are
estimates except for the SEC registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount&nbsp;Paid<BR> or&nbsp;to&nbsp;be&nbsp;Paid</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,214</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accounting fees and expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">204,214</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B>Item&nbsp;14.
Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Neither our articles of incorporation,
nor our amended and restated bylaws, prevent us from indemnifying our officers, directors and agents to the extent permitted under the
Nevada Revised Statutes (&ldquo;NRS&rdquo;). NRS Section&nbsp;78.7502, provides that a corporation may indemnify any director, officer,
employee or agent of a corporation against expenses, including attorneys&rsquo; fees, actually and reasonably incurred by him in connection
with any defense to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise
in defense of any action, suit or proceeding referred to Section&nbsp;78.7502(1)&nbsp;or 78.7502(2), or in defense of any claim, issue
or matter therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">NRS 78.7502(1)&nbsp;provides
that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation,
by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
against expenses, including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by
him in connection with the action, suit or proceeding if he: (a)&nbsp;is not liable pursuant to NRS 78.138; or (b)&nbsp;acted in good
faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect
to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">NRS Section&nbsp;78.7502(2)&nbsp;provides
that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement
and attorneys&rsquo; fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if
he: (a)&nbsp;is not liable pursuant to NRS 78.138; or (b)&nbsp;acted in good faith and in a manner which he reasonably believed to be
in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which
such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the
corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or
suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case,
the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">NRS Section&nbsp;78.747 provides
that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability
of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine
the question of whether a director or officer acts as the alter ego of a corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Our amended and restated bylaws
provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions
of the NRS, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth
in any stockholders&rsquo; or directors&rsquo; resolution or by contract. Any repeal or modification of these provisions approved by our
stockholders will be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers
existing as of the time of such repeal or modification. We are also permitted to apply for insurance on behalf of any director, officer,
employee or other agent for liability arising out of his actions, whether or not the NRS would permit indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">We have entered into indemnification
agreements with each of our officers and directors, a form of which is filed as an exhibit to this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">These agreements require us
to indemnify these individuals to the fullest extent permitted under Nevada law against liabilities that may arise by reason of their
service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"></P>

<!-- Field: Page; Sequence: 30; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B>Item&nbsp;15.
Recent Sales of Unregistered Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">In the three&nbsp;years preceding
the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Pre-Funded Common Stock Purchase Warrant</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">On May&nbsp;29, 2025, we satisfied
$12,713,858 of Company debt, previously owed to Knight Therapeutics International S.A. (&ldquo;Knight&rdquo;), through a combination of
(i) a $10,000,000 cash repayment, (ii) an early payment discount of $1,213,858, and (ii) a conversion of $1,500,000 into equity (the &ldquo;Equity
Conversion&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">On May&nbsp;29, 2025 (the &ldquo;Initial Exercise Date&rdquo;), we
issued a pre-funded common stock purchase warrant (the &ldquo;Pre-Funded Warrant&rdquo;) to purchase up to 428,570&nbsp;shares of common
stock (each a &ldquo;Pre-Funded Warrant Share&rdquo;), to Knight, in connection with the Equity Conversion. The Pre-Funded Warrant expires
upon the earlier of the date the Pre-Funded Warrant is exercised in full, and May&nbsp;29, 2026. The aggregate exercise price of the Pre-Funded
Warrant, except for a nominal exercise price of $0.00001 per Pre-Funded Warrant Share, was pre-funded to the Company on or prior to the
Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.00001 per Pre-Funded
Warrant Share) shall be required to be paid by Knight to effect any exercise of the Pre-Funded Warrant. The Pre-Funded Warrant may be
exercised, in whole or in part, by means of a &ldquo;cashless exercise.&rdquo; The Pre-Funded Warrant provides that the warrant will be
automatically exercised via &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) of the Pre-Funded&nbsp; Warrant upon the closing
of the next sale of equity securities of the Company. We relied upon the exemption from registration provided by Section 4(a)(2) of the
Securities Act for transactions by an issuer not involving a public offering to issue the Pre-Funded Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Issuance in Connection with Consulting Services
Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">On April 9, 2025, the Company
entered into a Consulting Services Agreement (the &ldquo;Consulting Agreement&rdquo;) with FMW Media Works, LLC (the &ldquo;Consultant&rdquo;).
Pursuant to the terms of the Consulting Agreement, on July 7, 2025, the Company issued to the Consultant 60,000 shares of Company common
stock in consideration for services provided. The Company relied upon the exemption from registration provided by Section 4(a)(2) of the
Securities Act for transactions by an issuer not involving a public offering to issue the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Warrant Issuance in Connection with Second
Amendment to Term Loan Credit Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">On March 24, 2026, the Company
entered into a second amendment (the &ldquo;Second Amendment&rdquo;) to its term loan credit agreement, dated May 30, 2025 (as previously
amended, the &ldquo;Credit Agreement&rdquo;, and as amended by the Second Amendment, the &ldquo;Amended Credit Agreement&rdquo;), with
ACP Agency, LLC (&ldquo;ACP&rdquo;), as administrative agent and collateral agent, and the lenders party thereto. In connection with the
Second Amendment, on March 24, 2026 the Company issued a common stock purchase warrant (the &ldquo;Lender Warrant&rdquo;) to Acme Credit
Partners Fund I, LP (the &ldquo;Holder&rdquo;), a lender under the Credit Agreement. The Lender Warrant provides the Holder the right
to purchase 3,000,000 shares of the Company&rsquo;s common stock at an exercise price of $0.00001 per share. The Lender Warrant has a
ten-year term and becomes exercisable upon the occurrence of a &ldquo;Qualified Event of Default,&rdquo; defined as the occurrence of
any event of default under Section 8.1(a) of the Credit Agreement; the Lender Warrant terminates upon the indefeasible payment in full
of all secured obligations under the Credit Agreement and related loan documents. The Company issued the Lender Warrant in a transaction
not involving a public offering pursuant to Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Warrant Issuance in Connection with ELOC Purchase
Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">As consideration for the Selling
Stockholder&rsquo;s execution and delivery of the ELOC Purchase Agreement, the Company issued to the Selling Stockholder a warrant for
the purchase of 1,540,000 shares of the common stock at an exercise price of $0.01 per share, subject to adjustment. Under the warrant,
the Selling Stockholder may exercise the Warrant during the period commencing on May 8, 2026 and ending on 5:00 p.m. eastern standard
time on the date that is five (5) years after May 8, 2026. In addition, the Company will pay up to $20,000.00 to the Selling Stockholder&rsquo;s
legal counsel for the Selling Stockholder&rsquo;s expenses relating to the preparation of the ELOC Purchase Agreement. The Company issued
the warrant in a transaction not involving a public offering pursuant to Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I></I></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B>Item&nbsp;16.
Exhibits and Financial Statement Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">(a)
Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">The following documents are
filed as exhibits to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024079034/ea020832409ex3-1_synergy.htm" ><FONT STYLE="font-size: 10pt">Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on September 16, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390025055656/ea024616901ex3-1_synergy.htm" ><FONT STYLE="font-size: 10pt">Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. with the SEC on June 18, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex3-4_synergy.htm" ><FONT STYLE="font-size: 10pt">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390026054186/ea028992901ex4-1.htm">Common Stock Purchase Warrant dated May 8, 2026 (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. on May 11, 2026).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">5.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea029095401ex5-1.htm">Opinion of Nelson Mullins Riley&nbsp;&amp; Scarborough LLP</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.1#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-1_synergy.htm" ><FONT STYLE="font-size: 10pt">Sales and Marketing Consultant and Distribution Agreement, dated April&nbsp;2, 2014, between Synergy Strips Corp. and Kenek Brands Inc. (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-3_synergy.htm" ><FONT STYLE="font-size: 10pt">Distribution, License and Supply Agreement, dated January&nbsp;22, 2015, by and between Synergy Strips Corp. and Knight Therapeutics (Barbados) Inc. (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.3#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-4_synergy.htm" ><FONT STYLE="font-size: 10pt">Synergy Strips Corp. 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.4#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-5_synergy.htm" ><FONT STYLE="font-size: 10pt">Synergy CHC Corp. 2024 Equity Incentive Plan and amendment thereto. (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.5#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390025055656/ea024616901ex10-1_synergy.htm" ><FONT STYLE="font-size: 10pt">Amendment to Synergy CHC Corp. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. with the SEC on June 18, 2025).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-12_synergy.htm" ><FONT STYLE="font-size: 10pt">Amendment and Confirmation Agreement, dated December 3, 2015, by and among Knight Therapeutics (Barbados) Inc., Nomad Choice Pty Ltd., Synergy CHC Corp. and Breakthrough Products, Inc. (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-15_synergy.htm" ><FONT STYLE="font-size: 10pt">FOCUSfactor Distribution Agreement (Canada), dated December&nbsp;23, 2016, between Knight Therapeutics Inc. and Synergy CHC Corp. (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-24_synergy.htm" ><FONT STYLE="font-size: 10pt">Distribution Agreement (Canada), dated February&nbsp;15, 2016, between Knight Therapeutics Inc. and Nomad Choice Pty Ltd. (incorporated by reference to Exhibit 10.24 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-25_synergy.htm" ><FONT STYLE="font-size: 10pt">Distribution Agreement (Remaining Territories), dated February&nbsp;15, 2016, between Knight Therapeutics (Barbados) Inc. and Nomad Choice Pty Ltd. (incorporated by reference to Exhibit 10.25 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-26_synergy.htm" ><FONT STYLE="font-size: 10pt">Distribution Agreement (Canada), dated January&nbsp;1, 2017, between Knight Therapeutics Inc. and Sneaky Vaunt Corp. (incorporated by reference to Exhibit 10.26 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.11</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-27_synergy.htm" ><FONT STYLE="font-size: 10pt">Distribution Agreement (Remaining Territories), dated January&nbsp;1, 2017, between Knight Therapeutics (Barbados) Inc. and Sneaky Vaunt Corp. (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.12+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-28_synergy.htm" ><FONT STYLE="font-size: 10pt">Costco Wholesale Basic Vendor Agreement, dated October&nbsp;9, 2009, between Factor Nutrition Labs LLC and Costco Wholesale Corporation (incorporated by reference to Exhibit 10.28 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.13+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-29_synergy.htm" ><FONT STYLE="font-size: 10pt">Supplier Agreement by and among Factor Nutrition Labs LLC and Wal-Mart Stores, Inc., Wal-Mart Stores East, LP, Wal-Mart Stores East, Inc., Wal-Mart Stores Texas, LP, Sam&rsquo;s West, Inc., and Sam&rsquo;s East, Inc. (incorporated by reference to Exhibit 10.29 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.14</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-30_synergy.htm" ><FONT STYLE="font-size: 10pt">Master Vendor Agreement, dated July&nbsp;26, 2022, between iHerb, LLC and Synergy CHC Corp. (incorporated by reference to Exhibit 10.30 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-31_synergy.htm" ><FONT STYLE="font-size: 10pt">Merchant Loan Agreement, dated January 29, 2024, between WebBank and Synergy CHC Corp. (incorporated by reference to Exhibit 10.31 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.16</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-32_synergy.htm" ><FONT STYLE="font-size: 10pt">Merchant Loan Agreement, dated May 1, 2024, between WebBank and Synergy CHC Corp. (incorporated by reference to Exhibit 10.32 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.17</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-33_synergy.htm" ><FONT STYLE="font-size: 10pt">Promissory Note, dated February 10, 2022, by Synergy CHC Corp. in favor of Don Sanders (incorporated by reference to Exhibit 10.33 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;10.18</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-34_synergy.htm" ><FONT STYLE="font-size: 10pt">Form of Securities Purchase Agreement, dated March 8, 2022, by and between Synergy CHC Corp. and the purchasers identified on the signature pages thereto (incorporated by reference to Exhibit 10.34 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.19</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-36_synergy.htm" ><FONT STYLE="font-size: 10pt">Modification Agreement, dated June 14, 2023, by and among Sanders Morris Harris, LLC, Mr. Don A. Sanders and Synergy CHC Corp. (incorporated by reference to Exhibit 10.36 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font-size: 10pt">10.20</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-37_synergy.htm" ><FONT STYLE="font-size: 10pt">Modification Agreement, dated March 31, 2024, by and among Sanders Morris Harris, LLC, Don A. Sanders and Synergy CHC Corp. (incorporated by reference to Exhibit 10.37 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024056991/ea020832401ex10-38_synergy.htm" ><FONT STYLE="font-size: 10pt">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.38 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.22</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390024073419/ea020832406ex10-39_synergy.htm" ><FONT STYLE="font-size: 10pt">Amended and Restated Promissory Note, dated August 28, 2024, by Boombod Ltd in favor of Synergy CHC Corp. (incorporated by reference to Exhibit 10.39 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on August 28, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.23</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390025050984/ea024464201ex10-1_synergy.htm" ><FONT STYLE="font-size: 10pt">Credit Agreement, dated as of May 30, 2025, by and among Synergy CHC Corp. as Borrower, each subsidiary of the Borrower listed as a Guarantor therein, the lenders from time-to-time party thereto as Lenders and ACP Agency, LLC, as Collateral Agent and Administrative Agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. on June 4, 2025).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.24</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390025081175/ea025480001ex4-1_synergy.htm" ><FONT STYLE="font-size: 10pt">Form of Representative Warrant, dated August 27, 2025 (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. on August 27, 2025).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390026054186/ea028992901ex10-1.htm">Equity Purchase Agreement dated May 8, 2026, by and between Synergy CHC Corp. and Hudson Global Ventures, LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. on May 11, 2026).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.26</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390026054186/ea028992901ex10-2.htm">Registration Rights Agreement dated May 8, 2026, by and between Synergy CHC Corp. and Hudson Global Ventures, LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed by Synergy CHC Corp. on May 11, 2026).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">21.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1562733/000121390026037883/ea028351301ex21-1.htm">List of subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Annual Report on Form 10-K, filed by Synergy CHC Corp. on April 1, 2026).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">23.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea029095401ex23-1.htm">Consent of RBSM LLP</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">23.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea029095401ex5-1.htm">Consent of Nelson Mullins Riley &amp; Scarborough LLP (included in Exhibit 5.1)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">24.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_014">Powers of Attorney (included on signature page)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">107*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea029095401ex-fee.htm">Filing Fee Table</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">#</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Denotes a management contract
or compensatory plan or arrangement.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">+</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certain confidential information
contained in this agreement has been omitted because it is not material and would be competitively harmful if publicly disclosed.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed or furnished herewith.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&yen;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certain schedules and exhibits
to this agreement have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit
will be furnished to the SEC on request.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">(b) Financial
Statement Schedules</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">All schedules have been omitted
because the information required to be set forth in the schedules is either not applicable or is shown in the financial statements or
notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B></B></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><B>Item&nbsp;17.
Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">(a) The undersigned registrant
hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(1) To file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white">(i) To include
any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white">(ii) To reflect
in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white">(iii) To include
any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material
change to such information in the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Provided, however,&nbsp;</I>that:
Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section
13 or Section 15(d) of the Securities and Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), that are incorporated by
reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(2) That, for
the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(3) To remove
from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(4) That, for
the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part
of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant
to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a
claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Pursuant to the requirements
of the Securities Act, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of N. Windham, State of Maine, on the 15<SUP>th</SUP> day of May, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>SYNERGY CHC CORP.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Jack Ross</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Jack Ross</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer and Chairman</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">KNOW ALL PERSONS BY THESE PRESENTS,
that each person whose signature appears below constitutes and appoints Jack Ross and Jaime Fickett and each of them, his or her true
and lawful attorneys-in-fact and agents with full power of substitution, for him or her and in his or her name, place and stead, in any
and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to sign any
registration statement for the same offering covered by the registration statement that is to be effective upon filing pursuant to Rule&nbsp;462(b)&nbsp;promulgated
under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents
in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to
do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and
purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of
them, his, hers or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25in">Pursuant to the requirements
of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>SIGNATURE</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>TITLE</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>DATE</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Jack Ross</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Executive Officer and Chairman</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">May 15, 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Jack Ross</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Jaime Fickett</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">May 15, 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Jaime Fickett</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Alfred Baumeler</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">President and Director</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">May 15, 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Alfred Baumeler</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Nitin Kaushal</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">May 15, 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Nitin Kaushal</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea029095401ex5-1.htm
<DESCRIPTION>OPINION OF NELSON MULLINS RILEY & SCARBOROUGH LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><IMG SRC="ea029095401_ex5-1img1.jpg" ALT=""></TD>
    <TD STYLE="width: 40%"><B>NELSON MULLINS RILEY &amp; SCARBOROUGH LLP<BR>
ATTORNEYS AND COUNSELORS AT LAW</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD><B>301 Hillsborough Street<BR>
Suite 1400<BR>
Raleigh, NC 27603<BR>
T: 919.329.3804<BR>
nelsonmullins.com</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 15, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synergy CHC Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">700 Roosevelt Trail STE 8 #1016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">N. Windham, Maine 04062</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RE:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Statement on Form S-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel
to Synergy CHC Corp., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the filing of a registration statement
on Form S-1 (the &ldquo;<U>Registration Statement</U>&rdquo;) with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;). The Registration Statement relates to the resale
by Hudson Global Ventures, LLC (the &ldquo;<U>Selling Stockholder</U>&rdquo;), of an aggregate of up to 101,710,000 shares of common
stock, par value $0.00001 per share, of the Company (the &ldquo;<U>Common Stock</U>&rdquo;), comprised of: (i) up to 100,000,000 shares
of Common Stock (the &ldquo;<U>ELOC Shares</U>&rdquo;) that we have reserved for sale to the Selling Stockholder under the Purchase Agreement,
dated May 8, 2026, by and between the Company and the Selling Stockholder (the &ldquo;<U>ELOC Purchase Agreement</U>&rdquo;); (ii) up
to 1,540,000 shares of Common Stock (the &ldquo;<U>Warrant Shares</U>&rdquo;) issuable upon the exercise of a warrant (the &ldquo;<U>Warrant</U>&rdquo;)
to purchase 1,540,000 shares of Common Stock, issued to the Selling Stockholder pursuant to the terms of the ELOC Purchase Agreement
as a commitment fee; and (iii) shares of common stock previously issued to the Selling Stockholder in connection with the consulting agreements between Selling Stockholder and the Company (the &ldquo;<U>Existing Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is being furnished
in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, and no opinion is expressed herein as
to any matter pertaining to the contents of the Registration Statement or related prospectus or any prospectus supplement (collectively,
the &ldquo;<U>Prospectus</U>&rdquo;), other than as expressly stated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As such counsel, we have examined
and relied upon the Registration Statement and the Prospectus contained therein, the Company&rsquo;s Articles of Incorporation, as amended,
the Amended and Restated Bylaws, and such matters of fact and questions of law as we have considered appropriate for purposes of this
letter. We have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having
independently verified such factual matters. Our opinions are based upon and limited to Chapter 78 of the Nevada Revised Statutes, and
we express no opinion with respect to any other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the foregoing and
the other matters set forth herein, it is our opinion that, as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The Existing Shares have been duly authorized by all necessary corporate action of the Company and are validly issued, fully paid and
nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. When issued and paid for
in accordance with the ELOC Purchase Agreement, the ELOC Shares will be duly authorized and, when issued upon receipt by the Company of
the consideration therefor, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. The Warrant Shares have been duly authorized
by all necessary corporate action on the part of the Company and the Warrant Shares, when and if issued upon exercise of the Warrant in
accordance with the terms of the Warrant, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>California
| Colorado | District of Columbia | Florida | Georgia | Illinois | Maryland | Massachusetts | Minnesota | New York | North Carolina |
Ohio | Pennsylvania | South Carolina | Tennessee | Texas | Virginia | West Virginia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing opinions are
qualified to the extent that the enforceability of any document or instrument may be limited by or subject to bankruptcy, insolvency,
fraudulent transfer or conveyance, reorganization, moratorium or other similar laws relating to or affecting creditors&rsquo; rights generally,
and general equitable or public policy principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We express no opinion as to
any matter other than as set forth herein, and no opinion may be inferred or implied herefrom. We assume no obligation to advise you of
any changes in the foregoing subsequent to the date of this opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion as an exhibit to the Registration Statement and to the reference to this firm under the caption &ldquo;Legal Matters&rdquo;
in the Prospectus which forms a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the
category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Nelson Mullins Riley &amp; Scarborough LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nelson Mullins Riley &amp; Scarborough LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea029095401ex23-1.htm
<DESCRIPTION>CONSENT OF RBSM LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference in
this Registration Statement on Form S-1 of our report dated March 31, 2026 with respect to the audited consolidated financial statements
of Synergy CHC Corp. (the &ldquo;Company&rdquo;) as of and for the years ended December 31, 2025 and 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the references to us under
the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ RBSM LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">May 15, 2026</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ea029095401ex-fee.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Template (c) 2024-2025 Novaworks, LLC -->
<!-- Field: Set; Name: AliasFileType; Value: Forms View; Template: Fee Exhibit\Fee Exhibit FE.xds -->
<!-- Field: Set; Name: Platform; Value: Novaworks Fee Exhibit Editor; Version: 1.4a -->
<!-- Field: Set; Name: Control; Value: VGVtcGxhdGU6IChkZWZhdWx0KQ0KQmFzZSBGb250OiBUaW1lcyBOZXcgUm9tYW4sIFRpbWVzLCBTZXJpZg0KQ2FwdGlvbiBTaXplOiAxMnB0DQpUYWJsZSBUaXRsZSBTaXplOiAxMXB0DQpUYWJsZSBIZWFkIFNpemU6IDhwdA0KVGFibGUgQm9keSBTaXplOiAxMHB0 -->
<!-- Field: Set; Name: MD5; Value: 471949ea525dec2390d4d4c663d55cef -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
  <title>Filing Fee Exhibit</title>
  <meta http-equiv="Content-Type" content="text/html"/>
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">

<div style="display: none">
  <ix:header>
    <ix:hidden>
      <ix:nonNumeric name="ffd:SubmissnTp" contextRef="c_report" id="fee_001">S-1</ix:nonNumeric>
      <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="c_report" id="fee_002">EX-FILING FEES</ix:nonNumeric>
      <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="c_report" id="fee_003">0001562733</ix:nonNumeric>
      <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="c_report" xs:nil="true" id="fee_004"></ix:nonNumeric>
      <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="c_report" id="fee_005">N/A</ix:nonNumeric>
      <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="c_report" id="fee_006">N/A</ix:nonNumeric>
      </ix:hidden>
    <ix:references>
      <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
      </ix:references>
    <ix:resources>
      <xbrli:context id="c_offering_1">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001562733</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-05-14</xbrli:startDate>
          <xbrli:endDate>2026-05-14</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_report">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001562733</xbrli:identifier>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-05-14</xbrli:startDate>
          <xbrli:endDate>2026-05-14</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:unit id="USD">
        <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="pure">
        <xbrli:measure>xbrli:pure</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="shares">
        <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unit>
      </ix:resources>
    </ix:header>
  </div>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: right">Ex-Filing Fees</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">CALCULATION OF FILING FEE TABLES</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center"><ix:nonNumeric name="ffd:FormTp" contextRef="c_report" id="fee_007">S-1</ix:nonNumeric></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="c_report" id="fee_008">Synergy CHC Corp.</ix:nonNumeric></p>

<p style="font: bold 11pt Times New Roman, Times, Serif; border-top: Gray 3pt double; padding-top: 6pt; text-align: center; margin-top: 0pt; margin-bottom: 4pt">Table 1: Newly Registered and Carry Forward Securities</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font-size: 2pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="width: 12%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 6.5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="border-bottom: Black 1pt solid">Line Item Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Class Title</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Notes</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Calculation<br/> Rule</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Amount Registered</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Proposed Maximum Offering<br/> Price Per Unit</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Maximum Aggregate Offering Price</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Rate</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Amount of Registration Fee</td></tr>
<tr style="font-size: 2pt; vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="22" style="padding-top: 2pt; font-style: italic; text-align: center; padding-bottom: 2pt">Newly Registered Securities</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_1" format="ixt:booleanfalse" id="fee_009">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_1" id="fee_010">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_1" id="fee_011">Common Stock</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(1)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_1" format="ixt:booleantrue" id="fee_012">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="shares" decimals="0" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_013">101,710,000</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_014">0.30</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_015">30,513,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_016">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_017">4,213.85</ix:nonFraction></td></tr>
<tr style="font-size: 4pt; vertical-align: top; text-align: left">
  <td style="width: 11%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Offering Amounts:</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_018">30,513,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_019">4,213.85</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fees Previously Paid:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_020">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fee Offsets:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 1pt solid">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_021">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Net Fee Due:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 3pt double">$</td>
  <td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_022">4,213.85</ix:nonFraction></td></tr>
</table>

<p style="font: bold 8pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt">__________________________________________<br/>
Offering Note(s)</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_1" id="fee_023">Consists of up to 101,710,000 shares of common stock, par value $0.00001 per share (the &#8220;Common Stock&#8221;), of Synergy CHC Corp. (the &#8220;Company&#8221;), comprised of: (i) up to 100,000,000 shares of Common Stock (the &#8220;ELOC Shares&#8221;) that the Company may sell to Hudson Global Ventures, LLC (the &#8220;Selling Stockholder&#8221;) from time to time pursuant to the Purchase Agreement, dated May 8, 2026, by and between the Company and the Selling Stockholder (the &#8220;ELOC Purchase Agreement&#8221;); (ii) up to 1,540,000 shares of Common Stock issuable upon the exercise of a warrant issued to the Selling Stockholder pursuant to the terms of the ELOC Purchase Agreement as a commitment fee; and (iii) shares of common stock previously issued to the Selling Stockholder in connection with the consulting agreements between Selling Stockholder and the Company.<br/><br/>Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on May 13, 2026 ($0.30 per share of Common Stock). This calculation is in accordance with Rule 457(c).</ix:nonNumeric></td></tr>
  </table>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ea029095401_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029095401_img1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !7 : # 2(  A$! Q$!_\0
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MTMGZH****@]4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3TPVY["XD4G_ (%C'Z5[C\(/V4_"'PWTZWGU*R@\0^("H:6]O(PZ(W<1(>%
M]<9/Z5ZS/X7T:ZMV@FTFQE@88,;VR%2/IBE9CO%=#Q'X7?MG>#_'=Y!IVKQ2
M>%]2E(5/M3A[>1CV$HQC_@0%2?%C]JV+X7_$B+PH?#KZD9%MV%VMT$'[T@?=
MVGIGUJC\8?V,_"_C&RN+SPK#'X;UL*66*(?Z).?[K)_!GU7\C7Q?J5OKVG>/
M-/TOQ)]H75-,NK>R:.Z;<T:)(NU0>ZX/!],4FVBXQC+8_4W7]0N-*T2_O;2S
M;4;FWA>6.T1MK3%1G:#V)Q@5XM\&/VL]'^+WB]O#IT:YT.\:%I8#<S*XE9?O
M(,#@@9/X&O>*_/K]H[PC>_ KXZVOBC0T^SVEY.-4LBHPJRAOWT7T).<>CU3=
MM3.*3T/T%HK#\$>+;+QWX2TK7]/;=::A;K,HSRI(Y4^X.0?I6Y5$!7S]XJ_:
MZL-&^*,G@?2O#=WKU^MVEBL\-PB(T[8!4 @\*3@GV->E?&CXAQ?"[X;:SX@<
MK]HAB\NUC/\ RTG;A!^9R?8&OE3]B#X=R^*/&VJ>.=4!G33BT<$D@SYEU)R[
M^^U2?Q<>E2WK9%Q2LVSK?BQXLU3XK?$4>'M,)DLH+DVMK IPLD@.&E;\CSV
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MC\Z'NAKX6?8M%%%69!7Y_P#[6X _:6MB  2MAGW^85^@%?G_ /M<?\G*VO\
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M=17?B"_N?$TL9#"W=!!;9]U!);\3CVKZ/M;2"QMHK>VACM[>)0D<42A511T
M X HHII6);;W):P?'?AF;QGX0U70X=1ETEM0@-NUY"@9XU;AL ]R,C\:**8C
M@/@5^SEI'P-FU6YM-0GU:\OE2/S[B)4,<:\[ !ZGD_05Z[112M8;=]6%%%%,
#1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ea029095401_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029095401_img2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &T PP# 2(  A$! Q$!_\0
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M0^@RGX&>A4445^+GOA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?GA_P %=_\ CS^%G_774/\ T&&OT/K\\/\
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M&#Z&@8448/I1M([&@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK.+4FMKWLD[772_SZG%C\73Q?*XIW7_ * ^^G^\/YU_07H?_ " M,_Z](?\
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MG5.VOHSHE-.TUKRR=_Q7ZES]BW_D/_''_L>)?_1*5\W?L.?\G7S_ /7AK_\
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MZ'Z&OW<_9E_Y-R^&'_8N6/\ Z)6OD?$C_>(>OZ';E/P,]+HHHK\6/H HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#YV_::\"_$'5/B/\,O&7P_T&R\0WGAB>YFEM+^[^SQMYD9
M0?-U[D\>E>0Z=XQ\8_$K]MSX1Z?\1_"^A:%?Z);ZE-!:Z5J!O,.8=P:3/W&4
MJ"/KFON<=:^-O"-C!X/_ ."AVN+K_A(S:AXI@\_P[KSR#_18X;=A/M7J=_W?
MPKZ/ XCVE&I"45>$)6?76]^MM+M[7L>=6I\LXM/24E?M_6B.6\(_$OXI:]XE
M\4^+=%^*>FS:K8^)M0T]? ?B2X2*QN+2.1D01XPT; +PV>M=%<?ML^/_ !)=
M-X<TGPSX.\,ZZY\G^T]5\3QW-M;-C!<1JH+D'D#...:X&Q\ _"G]IWXG^*I(
M_!!^'.@>!-0O+SQ5K\%WA]5^:0>7N',88I)(Q'..!R:O2_\ "'ZMX&FU[0_V
M3;34?A7&A9-6\^.'59[<=;B-,;^GS#+Y/K7M2I8:<DIT;R5M/=7+?97YDI-[
MI:NVYQ<U:.U33YN_?IIZG<6'P%^&VK_#4Z#/\3;&^^)=[J@UO_A+H+M/M9U0
MG*N@!SM!P OI5W7/VFOB[\#X8M(\>^$_"_B2^BPB:W9>(([#[4O]]X74E6/4
MXP*\=^,7P/\  ?A;X&?";Q/\%],2^U_6_$=LNDZU.#]LE$OF,D4ISC,;84\9
M_=\]ZZR7X:>$? 'C)O"-I\/I?VAOC$+=+WQ#JNM7(6QT\R#(3+@JF?X4"DXP
M2><5FX4:JO5;J)N6C235G9N]THQ\F]]+%7J0=H6CMJM4[^5G=G+Z5\1_&'@S
MXP6OQ@C\2>%6O/'6LV.BZEX/TNZ-Y&MJS)&KL^0?,3J& ZDCH<5[[\6?VJ/%
MVB?%_7_AGX.\-Z"VI:=';%=;\1:QY$"F:,,#Y.T%R,] W.*\/G\0_!CPC\1O
M#R^*_@*?!GQ,CU:SLX=%AGQ93)-*%6]A90$?RF"G&%(SW[=I\>OAWX2_:,_:
M2UCX>P>%/[ \0Z,MGK&N_$..8>8MBL6?)53T=MRJ">!M)[4JL*%2M"5:DU%1
M>NEDDU9Z2]Y):;MN_4<'5C3:A/5O_A]UI?\  Y;3!XC_ &8OB/JWC.P^(7@_
MXA^)_$J+_P )-I.IWPLY'E#E@;>0$A0,[0I&, 5Z5XF^+OQ@^*OA;[+'IWAW
MX0^&M0_T>Z\5W>N)?3"-N"ML% 57*Y&X].U>=>&-)\%ZGHUW<?"_]F&V\?\
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MI9@/;).*_"O2O^/./Z5]5X8*:J8Q5/BO&_K[USBSFW+"W];&7XBZ-]*_=O\
M9B_Y-P^%_P#V+EC_ .BEK\)/$70_2OW:_9@.?V;_ (7G_J7++_T4M>)XD?[Q
M#U_0WRGX&>FT445^+'T 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5\R_$C_D_CX,?]@75/\
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MM]/O=*LW:&XU:\C,@N91U$0_N#^]W^E?E6 RW$9E4=/#K;=O9>I[LI*"NS]
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M7 C@BE'6-",[B.YZ=JZ&Q_;-GN((I'\)H?,17PEV<C(S_=KR\TDLFI4JV/\
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M),6W'.Q0<#C)]*]?\<?LJ^#['X8^*?%7P_\ ',_BF3PQ(T&J6T]N%PRD!PA
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M9V_9S\02?%OQ9XF\1Z_!X7T/P;J3V-Y=%?,,TR#Y@F2 $"E3N/\ >  S1/\
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M *)>OP'TO_CS3Z"OWX\<?\B3XC_[!EU_Z)>OP'TKFSC^E?=>%?\ S%?]N_\
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M7Q)]6%>2_$C]ISP;\,M9N-(OC>WNJ6X'FV]I#D(2,@%B0.A[5ZU7YV_M4?\
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M:_\ 'P;&,OLZY^PK_3->-^!?V@? GB;PIX.\1:S\)_'-[?> 0;32+W[$91&
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M*<\/0C1Y''2+DGLY6T<?)QL?4WQ(@L+G_@IK\38=6N)+32I/A[,EY<0KN>*
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M[@%<DCUP!USGM7)&,H4W5Y7>ZL^FB]Y/^N@\-&4?WBB^9M)/I_>3]?T/1_\
M@DA_R;E\<?\ KNW_ *125X+^QMI7A/6_V5OC'9^.=5O-%\,R:IIYN;VPB\R9
M&&3&%7!ZOM'3C->\_P#!)#_DW+XY?]=V_P#2*2OFG]C'5?#'BGX8>./A=K-_
M?65]XAU&VU &RMO-86MHC33D'H&*IM4'J2*\&;M'Y'%A%S5OG_PY]U?$5535
M/V;EMR3 MA9B(^HWP8/Y5WWQVC4:%^T*;;_CY;1K??L^]_QYM_3->>^ /C/\
M.=>\(^"+S5/"OBZ]D\%((M,NEM]ZLB@",W#*0H?"H2IX#"O*+/\ :VUW3_VD
M_'0O? .K>*-#\4P11W>A:? TUU9I&AC0E<8(*,0P.,YX->13J4XU)^]?G?3I
M:-M?FCZ2M0KRIP7(U[)-:VU;J<VGR'_L0R>9\8?&9'3_ (1F$?\ CZU>_9_\
M07?A/]D/4=9L=OVNQ\6^?&K=&(FCRI]B,C\:GLO'OA/X/:G-\0O OPWUZR\/
M6;OHGB>SO'8WJ"2-)862)BVU(PC9+$#YL9J4_%/P!!\-]'T+PYX!UW2?!.H:
MH-2OEU*%X?M"EMS+$68Y).TCY@ %XK"C%87"Q@YI.*:OKUV?H=%?GQF-E45)
MN,Y1;6E[1NVGKNUMZGS)^W?X<TFYLK/X@>'7;^QO%<SRRVS?>M+Q!B:,_4G/
MUSZU]#_\%1/^3//@9_O6O_IN%?/'[:GCKPCJ'@'1O"?@S3=4L=-T^^GOY6U6
M-E=Y9!M.TL26 (.3T[5]#?\ !43_ ),\^!?^]:_^FX5ZF'2Y':U^MMKZ7M\S
MYS'\WM8)IV2LK[VN[7\['._#?1_"&I_LK? 2;Q-K%YINHVE[/)HUM:P^8E[<
M&XP8Y3@[5QCGBOJGQF&_X; T@\\+:@?3R)J^+_@SKO@WXB_ #X?Z5>:CJ\,_
MP^CEU#4(M-M 7>6>Y5+=$=_EQN(9CV -?6UW^T!X&FN+7XBW_A+Q+<>*+2S6
MU5+6/?:2R<J-L@.UF^=@#UPW0FO.K\M22BY)6E&7JHO7_(TY9Q5U%NZDOOV(
MOBD([?X4_%E[7C/B\/-L_P"NEINS^E>#?LC-N\+?']LYS:YS_P!LYZRO@)^U
M/JFI^-OB1X;\5^!-4\6Z%XEU.;4+J'28'D>Q>0!7C9<?=PJ=P05S75:!\0_!
MGP?\WQ#X>\ :Y'\,_% FT35TNI3)>QWL3G,DBLQV1E9=G+ D].:KEC/$QQ*E
MHHM6^;U_$QM)4W2MUO\ EI^!W>C>+Y/ OP1^&VKB+[3;Q7]XEW;X_P!; RRB
M11[XY'N*^??V>_AW9?#?_@HSX%M-(G^U>']1$^JZ7-GK;36DS*O_  $Y'X"O
M;?%WCGP5=Z9X=\/-X7UO3?!.FQSR^5.6BO)'D0A9(@6RP4LQ)R2=W2O(?@3X
MXT7QK_P4&^%47ARPO=/T'1;"33+2/4(RDS*EK.=Q!YP=W&>O7O3PLO>5-34E
M'E6FZ:6OR>EB:\7RN3BU>[^5]/GN?K/1117O'B'\[%O5R#_CYM_^NJ?^A"J=
MO5R#_CYM_P#KJG_H0K^U:?\ #/@9;G]"ME_QXVO_ %Q3_P!!%?G+^VO\3M.^
M"O[??PW\;:SI4NL:7I>@QR2VL(4NX+7";DW<$J6!YQTZBOT:LO\ CQM?^N*?
M^@BOE+]O+_AGF2P\/Q?&A[V/62DATI]"#G45BR-_W1CR]V/O\9Z<YK^0\KG&
M&*M*+DI)JRWU/MZR;AH[6/E'0_VY?!FB?MI>)OC(FB:U/H.HZ$FFV]@(XEN?
M."1#YAOVA<QMSD]1Q7KO_!)Z_.L77QDU,1&*.\U&UG"DYV[S.^W/<@&OG2#1
M_P!B]9P[>(?BA)'G/EFUC&1Z9VU]\_L.^+O@OJW@[7-"^#.G:E8Z?I<\4NHR
MZK RSW$L@8*[.Q)<X0CL .@YK[',G2HY;4C1HS3DH1;:LDHO3_+YG%1YI54Y
M277\3WOQQ_R)'B/_ +!EU_Z)>OP'TK_CT3Z"OWX\;_\ (D^(_P#L&77_ *)>
MOP&TO_CS3Z"OM?"O_F*_[=_]N/-SK:'S_0S?$'0_2OW4_96.?V9_A9_V+EE_
MZ+%?A7X@Z'Z5^Z?[*IS^S-\+/^Q<LO\ T6*\OQ)_CP]?T-LI^%GB_P#P4Z&?
M@!I/MKT/_HN2ORR\1G_BFW_WY/\ T77ZH?\ !3<?\8^::?37;?\ ] DK\L-?
MB:;P_P"6@W.TCJH]28ZY>&]<HDEWE^AZ=7XS],/VU]5^&EA\(_AW'X^\/ZWK
MFH3Z-.-%?19_*-M+]CCWM)\ZY4Y3CGITKSK]NHJ_[./P#>/!A.G28*]/^0<F
M/ZUG?%/XK_#K]JSP[H._4O$7AO1_AGX<GU77S_9\?VJ>-T@MTCM]S%<E\_,W
M057@_:+_ &?_ (J_!OPY\/?B;)XITJT\*2;-+U*!5DFNK5%,2/(T.X*6C.UE
MP!QD&O@L%?"5*-9PFW2E>:MHEI:W9O6]_(Z9>\FNY]9^$$MSXD_9L>;'VE?#
M-X(]W7FQMMU?E[XM$@_:\U02Y\S_ (6 =V[K_P ?X_IBO?/BE^W)I-[\=?AY
MXO\  ]A,_@OP%;R62V=RZPRWL4RB.8A<GRP(T0)NY)'.*B^)/B+]G;XZ^)-9
M\<?#/_A*+WXP3+_;=IX<AA>*":[M]LKO(""H^6,EB&P>M5A85LJC*KB*;M5A
M)+Y]^VWW [3T3V9[!\6O^4I?P]]K"W_]$W=9A^+GAV]^-/Q?^#/Q.C:3P)XD
M\22#3]21MC:7>,(]N6_A#.%*O_"W!X-(?VN/V8?&GQ(\-?&G6;_Q!IOCG3[
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MB#5?$O[#/[1]WK&J7NKW@VQ"XO[AII=BV\>U=S$G SP*Z[PI+:?MG_LI^*?
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M&XP2TD[2(9=TAZ'#Q@CCCFOF/7?%7_":?$"_U[^R[#11J-P;C^S]+C,=M 2
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M?:8MZ;7P_N%Y?3/(ZA=R_-M58\X&.I)K]"++_CQM?^N*?^@BOS:_;Z^)NJ_
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M/$=L\-WIT3(PP5VAE_[Y((KZ3"<34Z;_ -KP=.=]VHI-^NC3^Y')+"0>J/R
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M /2CRL;IB(K^NA](2?$/Q/X'_8<^"UAX9TZ+5'U_4;VQO8#8?:IOLXE=G:(
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M4DFTI4I64;WBHZN_EMV=_(]'"24J-DU]I;[.^B/JOX/6$6I/\!=>N<3:I:^
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MQD\5\MQ#AI2P,<79.-.5FG?[:LGIVWWWL>KAZRC75'K):?+4^BK7X3^(X?\
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MSG8]W<%/R\RO:O!_@K0/A]H$&B>&=&LM!TB#)CL["$11@GJ<#J3W)Y-?/_\
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MQ1K.J_$S5-&FDV>&]%EB@TVTAM(X882;:(L054$NPY.2<YKTOX@?"SQ;\4_
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M3UK,UWQIX6\46.FZS\5/A[XJ'BJ"TBL/MNFW8L;36!"H6,SB6,LCA JLT9Y
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MR[2'X Q@Y(/:OL<LJ4,1RJL[VMIY]_--?B?*8^G6H3;IPT=]?R7E9]>WH4_
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MM_B6R3T\^R\SDS\5M3\RW\_X8S>)K\PK(VHVVG&TC7(&8PLREAL"[,YY*C
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MHJ*;XAZ=+"K+;W?S=-R ?GSP/?IVZU6MO$<6K3^5%;SQ_*S%I !C! P>>IW
MUZ,,50J.T))MGG3PE>FKSBTD,UX_\2R<^J'^5==\;3CPQ\-_>4?^DXKCM<.=
M+F_W#_*NO^.!QX9^&@_Z;#_TF%=:V.1[DBZ<VHV%LHB,Q1]X43F+!QC.1U^E
M/O?#]X-/=5@NDR<_+J.3W QE?0FJTPC;3+7S8;B8;S@6YP0=AY/^>N*J75Y:
M1Z=@+J87S>1L&XY .#W XQ[<BO#Q=2A"J_:4TWWO9_E^IZN'A5E37)-I=K?\
M$QY?#U[$LJ):W\8="I(U,-P0!@9'!'7/UJOJ>B7=Y<2O+:WL>X#'EZ@H . .
M !Z#\\ULV6N6]EIHC"W4R6\'FF1E!++NQC(X)SQ^%4[OQI9N!B"YY'&5 _K^
M7KVI)Y?R)225[.W]?,;6-YGRMNVES(@L)H+HR3030B-3M:2Z$NXD8Y&/2KWP
ML_Y*QH7^]+_Z+:J_]L+J:RE(I(PJ@YDQSDD8^HP:L?"S_DJ^A?[TO_HMJ]:@
MJ2A>CLSSJSJ<UJFZ/J.BBBN@YC^=6(XJS ?]*M_^NJ?^A"JL=3P'_2;?_KJG
M_H0K^RH2M2/A7\1_0[8_\>%K_P!<8_\ T$5\>?&SXP^-?#O_  4(^$W@?3/$
M=Y9^$=5LX9+[2(RODW#$W&2V1GG8O?M7V'8_\>%K_P!<8_\ T$5^8_\ P5/\
M.^+O#OQR\'>/=$AU*UL_['6SM]8TT.&M[F.20LN].48K(".F03CH:_E#*J<*
MV)=*=O>4DK][:'V5:3C#F1J_M\?MU:PGBR;X;?"[7)].ATZ3RM9UO3'Q-/<=
M/LT+CD*IX8KR6X' .?5O^"8WQP\7_%;P3XPTCQ=J]SKTN@W5O]DOKY]]P(Y5
M?,;L>6 *9!/(R17GW_!-S]C&XL;VU^+7C_3)(;G=N\/Z5?1D.I/WKR16Y!.2
M$!YZMZ5N_P#!+N)X_$WQTW1M&#K,6-RD9_>7/2OJ<2L#'+,1A:$4W2Y&Y:7<
MG*S_ *^70Y8>T=6,Y/>^A]O>-_\ D2?$?_8,NO\ T2]?S_:0_P#HR_2OZ ?&
M_P#R)/B/_L&77_HEZ_GVTV3;;KCTK[+PQGR?6?6/_MQY^;JZA\QNI-N=OI7[
MF_LF?\FQ?"[_ +%^U_\ 0*_"Z[;<[?2OW0_9*_Y-A^%W_8OVO_H-9^(KYJ=-
M_P![]&/*E9M>1W7CA@GA^5R-VUU;'T-<CX.NK2ZMI9;/"QLQ+J!@A^X(]:ZO
MQ\H?PU.K$@,ZJ2#@\^E>86'B32_AUX/UW7=;O1;Z5ID;7%U<[<E44?W1SGH,
M>]?B=.#J>Y!7DVDDNMSZ"[3\CT7=2;O>OGJ']M/PO?6^GSV/A+Q??0:A'YUI
M+'8QA9DR!N&9!@<CKZT6O[8FGZA--#:?#[Q;-+%(\3H4MD(96VL.9>Q!&?8U
M[7]@9FMZ+7JTOS8O:P[GT)NI-U?/.H_M>KIMQY$WPZUZ!PAD8W%U:HJ#*CYB
M'(7EEZ^M9X_;)NIY+M+3X=7$[6WEE]VO6B$[U#KM!.6^4@\=*J/#V925U35O
M\4/_ )(/:P[G3_M(_"B3Q7'IWBG2+2XGUW3E^RS_ &:XDC>2R)+,@5&&<-@^
MM?.&G^&M2G\17BBZEFCE39':Q7-RTLT@V@*5#;QQQ\W'OTKUMOVUKQ3*#X&M
M8'BW>8D_B6W5D 8C)&WD9'&,Y!!JM#^UY<R7CWMOX/\ "]M-(G_'W<>)(4>1
M<GCA-W'7Z$&OHJ&!SRC15)Q=HZ*U2.U[V^)_)KI\FL7.*;<6M>ZO]W]-'MO[
M.7PV/PW\,017=LMOK>HSF[ORLC.2W(C4EB>53"\5Z9X[*KH#.RA@DJMCZ9KP
MK]E_]I23X[>*?%.DW&@1Z5<^'9XXWN[*[^U6EP'!^Y)@9(Q^5>Y?$%1)X;E0
MDJ'=5W+U&<U\CFE'%4,9..-5JFC>M]TFM4WI9JVNQM#EY5R[',^#Y+22S=[+
M:(&8MM7C:V>1CMSVK?+5YYIOB/2OAYX-UK7=<OH[/2=.5I[J[(X51QG YST&
M/6N)C_;-\!7*V36MAXGNUO8Q-:M%HT@$Z$@!E)(R.1S[U-'+L7C.:>&I2G%.
MUTM+[[^@*:BES.Q[QNI-WO7@]I^U_P"&]2+C3_"7C&_9':,K%IJ [E8J1@R
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MS4W>R3]/Z1]G1'&HV_\ O'_T$U\[:YXBUFSUN6TTR^BMV6(M%:FW21[B3@@
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ML<DOGR1J%:4C!<@<L?KUK">YYN*337-)7\DX_HCL_@S_ ,B]X^_W?_:#5A>
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MQ!8)>:9J$9MKRV8X$J^N1R.Q![8KCK']D#X<:5:K;VZZ_';*H01'79]JJ %
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M,^Y\#^-OVH-3T/3;BYM=!M99(E)6)9LLWL!FO0/V&[7XD_&;Q!<_$+Q[9_\
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M "BBB@#^=$=*(C_I=M_UU3_T(4G:B(_Z9;_]=D_]"%?U57=J9\;'<_HHL?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&!Q7?_!/Q#K_ ,=OV"OBS9>*]7N]>O;:X=;>\OY#+*F%BE7YCSPV2/3-1?\
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MK:S?^@-5NJFK<Z1J'_7M+_Z ::W _(GX>>+=8N/ FA16>@>&KK3Y52&_EO\
M4C'*T*A[<JZ$_*I*PG(_B"C^*L[XEZ_?^)?%'A2PU/P?H%DDVI33LMC?B87N
MR 1KY@ ;"H=_8_,6'\-><>#OB'X5T[PU_9>M0ZJMW&3");-8V38+G[0#AB#G
M>BK]&)[8JEXF^(6@7'B70-2L+2XU&VL#/)/:WJ+'O>:1I6 P3D*SD#UV@]\5
M^OT\MJQQDY*F_MV=GU3MKS6[?\ \:5:/LTF^W_!/4M?\.VUEI&IRMX/T&WDB
MM9I6:.920-I^;!BXP1P!@_I7SQHPS8IWY/6NX\4?%+PUK^C7=O:>$O[*O9$9
M8YX)AM4D8R< '\*XG2.;0?[Q_G7Z'P=AZU"M/VR:;77Y?WI'DX^<917+_7X(
M_1']@[4+G2OV3/C7>V=Q)9W=M]HFAN(6VO$ZV)*LI[$$9!K2_8BOO%?Q(^#O
MQGTOQ#-JVI>(-:T]9+.[U<R%[N-[62%-DC_?4,%&02!N'K7R-\!OB9XHT/6K
M'P7I_BYO#/A;Q!J$,.JI)&'MY4<JC"0;2Q#+\G']X5]._%FU\;1_'7Q=XJTK
MXWVOASPOX9O9;*6]=YQ#H)<H$TU+?9B:1E0-LC!7"Y)!Q7PO$F73PN8XO#UG
M!.O)5(R:DVDGI%6B]9/=>2ZV/6P=53HPE&_NJS6GW[]#0^"OAS7O@%^P5\5;
M[Q=I%UH%_>7$C6]C?IY<SY6*%?E/(W-NQZXS2?\ !0[X(>+_ (]0?#CQK\/M
M%N/%=A)I7D2)IV'=!(1+&^,\J0S#(Z$<UY]\8_"/Q-^-?PPD\3)\8;3XI^&+
M;4+2QL]-TZ![>:6]FD$2H]OL78Z[U.7SD-D8JKH-QXR^!VB7G@_1OVEM*TGQ
M%IL;R2>$XDDFMXI%!:2VCNG0QB7@C:O&[CK7DVG[9YI"O%XESFY0Y9V2:2=_
M=NK>>GF;V7+[!Q?)96=T>C_$SX.^,OBK_P $^_A/X9\+:'-JWB#1]2ACO]/C
M=!) T+S12ALG&4?@\\4?\%"?A%XV^+'CSX=:3X$T^75?$7ASP\;^ZMK.=4GA
M0S)&CIDC)WJ<8.>,UD^,_#_BSX/?$;QK>^!/C<O@'X>031WGB%M1CEN1I]_<
M1HXB5'5O/N)BS28BX ZXXK@O!'@;XI>)OBUHWC7X?_'A_$MKXLN&T6Z\7Q12
M)+9S)$TR6UW;R#**0A*X^7TQW\6@YPJ+$1G&RYI*ZEO+5J73;9)W9T22:Y;/
ML>K_ +66F>(=0_87\#:E\5+1+7XEV%_#;J\I4W#!BX;<1QN:)59@.Z@]:^5_
MV7;)Y?B>FHQZ#9:^=&LIM5:+4F?[- D(!>5D1':5@.%0*<LPX.*=^TEXLU'Q
M)JVDQW_Q@E^+,]N)8YW6VEM[>PF5MK+&& 5PV#AU R!]*Y?X1>,M&\!>);C6
M=9TB375CL)X[2Q$OEQ/<NNU&E(.=BY+8&<D+Q7[EPIE]:GP]7IQ]Z55R:BDU
M:^G*KN+7WI:]CYG'58O%Q;TM;^NI]ZQ^'-=31%^S^ O"L^CF*0W>G2-,\SF>
M,LGEK]G#<FZ!8@D J%)78:9/HNN6$FE&^\"_#[R[B(:?#(UR\J3BXF7:NU8<
MK*LP&XGH(9!PM>(6W[3?P>M@"WPRO;J01".-Y6C7RQM7<AP_[Q=RL><?ZP@;
M<"J$G[1?P7D@EC/PJN;)IX4A-PD\;>4ZI(H>-6? 8EU8GJ6%>"LCS)7E/#32
M[V77=_QM]7K9]NB9T_6:/2:_K_MT]8N;75-0274++0_"]Y8ZK>V!6(W3+%:1
M%7$4<:&W!5)FC+8Y8[@3QT^%/VDM2EO_ (G:E%,EG&]BB69%C]PE1R2=J[F)
M)R<#T[5[5JOQT^$=QXFM-6MO T\=O:63VITA;J!;=96+;;AB&)=E4JB@XVX)
M!S7RIK4C2NTC.96<DERVXM^/>FLMGAN>M4BX^ZDD[>CVG*]K)-V6_75B=93M
M%.^O]=$?0/\ P34_Y/)\'_\ 7M?_ /I,]?MA7XH?\$T_^3R/"'_7K?\ _I.U
M?M?7XMQ!_OB]%^;/?PW\,*^*?^"EOC_0K'PKX0\/1:@EUXKAUE+\:3;N&E2#
MRG4O(/X!EAC.,YXZ5[7^V!\>W_9V^"FI>(K)4DU^[D73M)20947#@GS".X10
MS8[D =Z_,K0?A)XWOM=N-:UK5=(U&_U4BZN;ZXUB-Y69P"3(Q/!YZ9XZ=J]'
MAC+J=?%T\3B:G)"+W[M?H?5Y/A85*\:U6?+%,\_\3N-4O))9'6T9V#'>K,5Y
MSV7!_.M+Q'K%KXF32Q9>7:2V0VXPY\T8QUV\5Z=:?#W6+NWLI8[C2LW3K&D3
M:C'YBEE9OG49*XV$'/0D#O5^P^$^K:DA,&J^'V(;:5.JQJP.0.0<$#D<GBOW
M?ZMD\N;]\K3WU>K7G>Q^G*G@6W:LK2]?SN>L?\$O/&6AZ1XN\=>'M2U6.QU[
M4$MOL-E<R8^U*AD+^63C<PW#Y1S@YK]&>E?BE\5_AGKF@P2WB2:6;O2L7#R6
M>I)]JCP5PT6""V"1RI/0^E?HE^P-^T=??'[X6W%CX@G^T^+O#<J6=[<-@-=Q
M,/W,[?[1PRMZE<]Z_"^)\LHX;$SJX2KSQ5D_+16]?\S\ZSS JG5EB*4^:+?W
M'T=K7B#3/"NE7.KZS?V^EZ79KYMQ>7<@CCC4=RQ_R:_%^^U0:UKGC*?3][Z+
MJ&K3W%I=3@@R(9&*MC&0""*];_:S^+_B3]IKX[W_ ()\.7MI!X.\+32(D5Y=
MK!;W<\+!9I7)X9MQ*H.< 9'4UGQ^"-2M+2U\ZXTF-I)%A"KJ$8"DY^8Y(P@Q
MRW3D>M>#A**IINH[71^C<#Y?A,)SXC&UU"4DO=>FC3Z_,\Q\%W4/AB^OYYQ%
M=&[41B,!P(QW.=O.?2LZP*^%-9T:\OIV;2XM4BFFN;<-F*/S59CMQV /Y5[-
M-X(U"U21[B\TF"*,1EI&OT*_.A<#(R,X4@^AXJ[J?PJU2#39[A[S1+NV1"SB
M+4HW#+R.!_%T[9KLE1I3CRRFM->J_4_5*M/*YT'1CB$M'9]E+6^KUO\ \,?I
M_H7B+2_%VD6NLZ)J%MJNE7B>;;WEI()(Y%/<$?RZBK]?E;^R[\9M6_9I^.6G
M^&=0N89/ OBB:..6VM[H3P6\DC;([B,CA6#8##C*GGH*_5-E*L0>H.*^<G%1
M>CNC^5<VRR65XATN;FB]4^Z$KYN_;]\;:!X<_9T\0:3J6IQV^L:MY*:;IZ.#
M/=.LR,=J]=H .6Z"O8_BW\1[#X1?#3Q'XRU)?,M='LWN/)!P9I.D<8/^TY4?
MC7Y,Z6GB3XZ:_J/Q#\6:_IJZCJ5RT8.H3E6MT#(H2),';&OF* !V5CV)KR<=
MB'1IN,%>36Q[_">31S'&1KXBK[.E"2O*U]=TD<A>//?:9:(\:QM$F '/;\!4
ME@ZP>#[G0]J-+,&/VK!&TD_W<<XKTG5/AJVEPQ2GQ-H-RDGV; @N]SXFD\L'
M;C)V9!< 9 /2M.V^#$UQ<- WBOP];2JXC*W-UY?S>8\>!Z\QD\=BI[U\1_M6
MD>7SZ']4N61WE6==/3E;][9VWMMT_0U/V$?&NB>!/VB;=/$NI1Z.EYI$MC9W
M%S)M@EG9DPA8X"DA3C/?CO7ZGD8K\AO%GP/NCH:&XU[P]+!<G:KBZWB,[<_/
M@90Y&WGO[<U]5_\ !/WXWZWJ-QKWP>\7W\>IZSX;B^T:7?I.)_M%F&"M&)/X
MPA9=I_NMCM7T^5XF7*J56-GT\S\$X^R:A]8EC\#6YXI+F5G[JV6O7S/L>^U*
MTT>RFOK^ZALK*W7S)KBX<)'&HZEF/ %?FM#--XD^)_C[7M'O!_PCFH7-Q'%=
MS1NQF1I2RLJA3QWSUK=_:W^.&H_%CXRR_#?0KN"/0]"F9+A)Y-L$UQ&A>227
M'W@N-B)ZY/>O5_"MWI=GX>AC?6M&MGM56*5(Y@D8.[:2O8KP3GTKXSBW&XFO
M&-#"4>9)O7S\D?'Y3A98&*Q%=\JJ+1-;KO\ \$\#\&:;;>$O'5KKMQJ-M>):
M(R+9K;W&)2?XBWE_+CZ&L_XE^'KV75=3\26I%UI=Y>17,L-M')&]N!U #*-_
M?T%?3>C:[%K\,DUG<6[0QRR0M(6&T,D@C//H<A@>A7)SQ5HVXUG3[IK#4]+O
M)(T):-;D'/)&!ZGCI[BOSB$LS55570=]$[M;;KHK'M>UP\5:$]=?\CZ(\%^*
M=&\9^&-/U70-1AU33)8E$<\+AN0HRK#^%AW!Y%;?6OS7^'WQ,UW]G'XJ0Z_<
M7UE/X.UR\%OJEA9R_P"I#$?O&CXVLF[AAUPPZ5]-_MM_'^Z^#'PYLK#P_<^3
MXE\22/;6=S&?FMX N9)D_P!K!55/8MGM7] X3,HUL*ZU5<KBM5O]Q\'5RZI&
MO&E#53V??_ACR#_@H+XETGQ)XS\%>'=)U"._URP%Q]NMH'RMJKE-OF%0=K':
M>.H'7K7SGXRTEM5>0W.J0QW#QB-S]FF^7C&1A,&N^^#?@U]$BQJ^JZ+9WM_B
M7S)KDM.78(Q$KGO^]&3G&0_]TUZ#J'V33M16R&M:;=3-!/./LTXDXB905XZ,
M0P90>HZ<\5^7YIBL?7QLJM.@[>J\NZ9^MY7A\%A<''#UJUW\T>-7P@U_P/I/
MAZR>,SZ=+'*+CR)5-QM.2,%,)GU)-?3W[ ?C#2+2R\7>&+Z[2P\47&J?:X]-
MN6VM-#Y8&Z+.-^"#D#D<&N7N/#XMMOVG7=(@#,RJ'N=I.) F<=<9.<^G->7_
M !;^&FNG6[*XM-<TBRN[51=6EY#>[&W+D_NY1T88'XD562XC&X3%1G.C[KOU
M77>S1CG=#!8S"RA3JVDK='T[GZ<45XI^R/\ '"?XZ?"6#4=3*_\ "1:9,=/U
M,J,>9(J@K+CMO4@GW#5[77[)2J1K052&S/QFK3E1FZ<]T%? '_!6N"/3M(^#
MOB*3"I8:]+%(YZ!2L;G_ -%FOO\ KXB_X*YZ-]O_ &9]'O@FXV'B*!L@= \4
MJ_SQ7TF0M?VG13V;:^]-?J<U3X&?(.FW.JVFG^&;+?;ZUX7U^;59[BV.VXBF
MMG#36OF8R8SDS* 2"NYO6O!?BSINB6MCX,U'0[2[L+K6K:35'L?/W65KOF*K
M%;AOF4!D?.2<C;Z&N*\+^-]?\$27AT/5;G2S=H(KE(6PLRA@P5U/!P0#S6S\
M1?B0OQ!32I&TBVT>73H_L\5M89%NL62W"L20=Y9CR?O'IQ7ZOA,FKX+&PGHX
M:ZK3I+XH]_>2NNB.2512B>Z7WCO3=;NKW2?$^EM!-]OL]]CJ4 CD=E94E !X
M;'JI'6O ?BGI%AH7Q UFRTR(06$<JF&,$D*"BMCGGJ37Z%^);+0/'D7A[2_$
M>@)J?]H-]ELCJ"%HX MN':2*7[R[T. ?F&5]17PY^TI\.]-^&'Q1N-$TFZN[
MVQ6UAE2XO95ED?*X/S+P0,8'TKP^%\;1EF$L/&\7ROW=UHUJO2__  36K2E[
M&-7=/_@_Y'%:YS>61(QG3[;_ -  _I5&KFMG,^FGUTZ#]-P_I5.OW7('_L*7
MG+_TIGG5/B"O;_V(9_LW[7'PJ?.,ZTB?]]1NO]:\0KU']EOQ%I_A+]H_X;:S
MJM[!INF66N6\MS>7+A(H8PWS,S'H #UI\0ISRC%1_N2_(*7QKU/T;_X*(?M=
M^*/@$UIX(T31M+OK+Q5H-U]IN[XRF2(.7A8(%8#[ISSGFL/]N%QX@_X)T> =
M3@_>0QKH,Y<<X!MBF?S8"J'[5.D?"?\ :O\ 'T?BY_B"EU\/_AWX:FN?$%UX
M: N+EGDN<0P1[AMRV&YYZ8[Y'._#C]O3X#V'PKN_A1XS\/Z_JW@733]BTE]2
MLX[E[VQ5@\2W"JZ[)4;(RO&%4@BOYLP=-4Z.%Q&$H2E5HRYJED[;WBO)V7;J
M>H^JD]'L=3\&M4'A'_@D[JFI7F8XUMKZ5-P^\&O\+CZFG_\ !5;X?:S\0OAO
M\.O&'AW3;K6K+3Y95N?L$33-'%<QQO'(54$[24QGMD>M?/\ ^UO^W/X;^+?P
MJL/A9\+?#$_AOP+;/";B2XC2+?'$<Q01Q(2$3=AB6.20..N>K_9>_;$_:,T'
MX66FD^'_ (6W7Q,\/Z/%]FLM7^Q7(>*)>!$98^)0HX'<  9XKTZ6!S#"2AGT
M5&,O:R?+*23UL];M>?G;78ARBU[/R/3/^";OA/61^S?\9/"=WIMSIFNWLKF"
MSU")K>1EN+ I"Y5P"%9E."1CBI_@K\,/$W[.7_!/#XP67Q"T[_A'M0OH[Z6.
MTFE1W598([>/=M)&6<<#.<8]:X3XA^+/V@(+;PG^TAX&DE34_&&GIIVO:+:6
M<;6MN\=S]GM+86\K-)-(6+_-C<IST&:POC3\-/VF/VA-+;0_%?C_ ,(ZMK=D
MAO6^&FE:Q!#?*R*3\UO&-KRJ,_*SDCMS7!-SQ]>=6O6ITX5JBE+5MQE&]]$F
M[:O7;;4M+E2LMCT;]DG_ ()W_$7X(_';0?'6M^(]%&@Z5%++_P 2V64S7B20
ME0CJRJ$7Y@6R3]W\:^._VWO'>D_$?]J;Q]K6A3Q7>EF[CM(KJ$Y2<PQ)$SJ>
MX+(V#W !KU2Q\!:O<_ WPMXI^,'[1VO>&_"7B*"Y@LO#J_;+R[:6&1HC$\6_
M&Q=OS$C R%KXW("G"G*CH<8X[5^E<)4JN.S6KF.+K^TG"/(FHM1>MMVE=JW;
MYG)6M&"C%6%JKJ4S16I\L[6<A0P.-OJ:L5V7PL^&<OQ&\?>"](OX+RWT#6]>
MM='FU"!,!3*X#*C$$;PN3CFOT#B2M[+*,2[VO%K[]/R.:GK-'(^&/ O_  D=
MJUQ+>F,;R@ 3<3CODUTFK:G/X,T:"SM+W+QL%4R1K]W!_P#K5^@_P&^"OP%9
M/#-G8>#M8U6P\=:QJ>DZ;/KE^&GT]+)"DDW[O"DR2JQ'H,5C>(D\/?L]:U\%
M/A?IW@CP_K>J>/+BWN->U_6K07-TL;W@1(X2>$PJGV]N37Y!@\\R[+,L]GE^
M'G#%3@DY\S5U=\TE[SLE*+25E<N>'J5JO[V2<$]OZ]3X#O\ 28=7T"/5[SS+
MF]F" /T49;   %7O@]\'O%7QDUPZ%X0TQM6O;9'N;B/SDB6. . \C,Y  Y Z
M]Z_4/1Q8:-8>/HM+MM)T_P 0WOQ!UVR\,27-I&8(=02S_P!'0*1@=&"CH&(K
MX;_92M[77+WXQGQ;JDV@17.AS&_OH;<M)%*=0MR5$:XQN?"8' W'L*^7XGS*
MCF-"GRT%":Y5*5[RF[.\I:*]VNK>J/=R>#HUG).]DVM-%TV.T^(?[$/CC2_"
M/A>>QT&P^T^(-0M=.@MH+E3/!-,-T8G7^ ,H+9YP!S7I/PT_8BD\+V\MG%X[
M\->(9Y-5AT6XN-)1ITM;J4/F-F_V-G(Z\BOK/P0D9^+?Q!695#+XNTE;92<X
MD739-H7WP.*^?_V K6;_ (5<ZR1R&;_A:4/G J25(C<MN]/?-?G4(170_2XY
MYCZ>,6*A*,)QC'X8I*TDG:SNM+VON?$GQZ^!LOP0UW1[6]\1:;J^L:DDEQ=:
M79!A+IZ$YB$N?^>B,&&.G(K[C^ O[/?PM\/0R:0\GB/5Y+G5+70;MI98X5CU
M&:U6X>2,KR8HT:-0#R23FOEC]IJ0^.I_!/BR[LI;/7GOM0\,Z@9$*"[%G,IM
MIP#U)AG1"?6,5^@OA!=2U7[9K=[IMMI6C^$O%EQ<3W2Q"W62TM]."1W#D_ZQ
MGD5DWCJ5QVKRL73A4ERRBI+31J_7^F>12Q%5/VKFXR:EJM'?LK=WIYGCWPC^
M&_P[^'OQ!\/_  _N?!L.M>,[KP[=>+-5\47<S;H<B5HK:.,<!0%4D^OK7 ?M
MX^&O#V@^%-,DTWPI8S:QKU]9V=]K^3YUC*EM#*L2CH/.$KLQ/7;[5[;X*TK1
M_%OQDT/XIVWC#04T7Q+X&B\/P0M= W%G>F!@PF0?<7(89)'S<5XK^TYK7AC6
MO$]_:Z5XTL/$$_B3QAH-C!H-L"9;,6(,#W+>BR!E"GN#WQ7/&G#VFR[+:]M/
MF14J5.1N[M:[6MKW?R_X8^T?@Q^R9X+^$/B;1]<TK2]-M]4MH]HEM[((^6CV
MM\Y);N:^AZR8U']K(H_A9L?@#6M7TM:O5Q$N>M-R?=MM_B?#QBHJR"BBBL"@
MHHHH _G0'2H):G%12#@U_4];X#XV.Y5;K6OX3\:>(? >I?VAX:UW4O#]]WGT
MVZ>!C]=I&?QS60W%-%?&U8J4VFM#NBVD>VK^V=\=)+;[.WQ3\1&/&,^>H;_O
MK;G]:\V\1^*M;\9ZBVH^(-8O]<OVZW.HW+SO^!8G'X5A159'W:^BR_#4:*YJ
M<$GY)(YJDY2T;'#I10.E%>\MCG ]*_<S]CO_ )-9^%W_ & X?ZU^&9Z5^Y?[
M')S^RQ\+C_U X?YFOS7CK_<J/^/]&>MEW\27H>QT445^*'OA5?4$\S3KQ/[T
M$B_FI%6*BN_^/2?_ *YM_(T ?D)??L)3-)(]MKU\N6)_>6*OC)S_  M7!_$3
M]E#5/A]H3:I+JD]_&)5B6WM]+D:5B>^ W08YK[.U33/$]IK.J/I<]VT$TIDC
M6VNHSL9CR2A([=JY;]I?QQK'PW^%6FZN[0R:E_:L:QPW&<;60Y#;6!) SD@B
MOH<NXNSO$XA8>%V[V2<59ZVM>U]3NK9+@J,85*E5<LK7L]5IVU/D_2?@MHNN
M^%[73K/6(O\ A-[J53#:W$[PKY3*7R\)4E2 "/PJ_<_LF_$O0/":ZW%H7]N:
M8LDBR2Z/)]H>+:<$M'@-CW --^&'B7Q#+\9O#OQ(O=.,EBU[%]I6'#QI"^8-
MWWBPP&)YK]DO VG6[^$=.#1*&4-AD&T@[CSD5]G1SS-^%,1"K4G&M[5<[3=^
M7FW@FG[O+;1;+L>/C:>$S&T*,.107+=*W-;[3TU;/P\\&NMKXTT(SGR!#J5L
M9?-^7RP)ESNSTQ@YS7UA\1Y-#^-5]\6O &F^)]'TW74\>7'B71I[^\2&RU:)
MX1"\2SYV!UV[ER<')'KC[7^+?[*GP]^,,<DFN^'X&U$CY=4L<6UXI_ZZ*,/]
M&!KXA^+_ /P3=\7^%_/N_!&I1>*[!02-.NP+>^4>@S\DGX%?I7V'^L64\3XR
MCBJM=X6M324>9*4>924D^;16Z-24?4\58:M@J<J:CSQ>]M':UMC?^#%SHG[)
MOPQURZ\1>*-"UKQ-_P )#H^HW/AS1]1CNI(+6.4J6#*=KR[6=MJDX"+D\UXC
MXS_9GM7UG6/%=I\3/!MUX',LVHVVJ/JJF[G4DR)";3_6"8DA2I&,Y.<5XQXC
M\.:MX0U632];TR[T;4(CM:UO86A<>O!'(]QQ7+ZEP"PX/K7T%7AS$X:5;'PQ
MO-.M\34%9IVVUTVT?9G-'&PERTG3TCMJ?;GQ\\0>%/V@;WXC_#73_&6B:/K!
MUZQ\1Z)J%]>+'I^I_P#$OB@FMVN/NJZE<J3QU'%._9AOO"_[*[6/@[Q%XW\/
M:EXB\2ZPM]J)TV_6>QT>UM[:<(9+@?(99'<* I.!U-?GQ='YB2>/>NR^'WPE
M\2>/;J%=/LOL]K(P'VR[S''^'=OP!K\RK9?2H4W0JU>6GUO;>V_X7MW^X]B-
M9R?,HW9I7>E)9VUK?+?VMQ]MDF8VT+DR0;7('F#MGJ/:NL\!_"[Q'\0Y$_LF
MRCCLB_EMJ>HW"6EE&?1IY"%SWP"3[5]N?LV?\$]-"TZ"TUCQ;9RZ_<8#JNHJ
M8;4'VA^\_P#P,X]JZG]L5? OAS4_ NA>+-,LV\/6:WCVT'V=A'&WEH#LCCQC
MCBOKI>(U+ 4XX7+Z3JRVYK?E'1R^;C\S/!Y#+,,0H5:B@G??R3>K\[?>>#Z)
M^Q%X1N+&#^UOV@/!=EJ1'[ZWM)HYHXSZ!S*N[ZX%6_BC^R'HW[-7AW3/&>H>
M-X/$]I<WD-I%;PZ> "),D2JV]@0 O!'KUKGWU_\ 9I71KB2/PU9O;),L;,VE
M7(S*4.T9\WO7&_%+XUW'[0&D^&O"EAJ>B^%_A]X5MH+&SL;V\%NUS<QQC=*^
M06V+DJ@/'&3R:^:CG^=\5MY7B*\J="JFIN4817*]^62C>_1=?,^FJ99A^&*M
M+,:+C5G"2:7FM=5S/3N>AO\ 'CX,S:)K$$'@^426]NB&=M(M59B254Y#<G)!
M)QVS7#P_L=:Q\9O#EGXU\/KJ;6&IAC';VNE[E78Q0X(;!R5)Z5Y=8?#K3KJ.
M2?\ X2_PU"J,4+3:OA6.XCC P>F?IS7U?^PC\>=6^%GQ1TCX0:IK^G:_X0UV
M2>'2A8W7GG3+U09-JM@?NI<MQSACD8R17+C>#:/"]&689-C>>=G&2[Q;YKI.
MZ>R[;.U[V,\5Q36SNE]3Q-'ECS*2?6Z35O35_@5/V+OV0O%WPA_:2\-^)M4T
MW5X=/MX;N)YKNQ\J,%X649;)[U^FM071.^WY_P"6H_D:GK\RQ&)JXJ?M*SN_
MZ['+&*@K1/A[_@J7&L_AKX3Q2C?;R>(G62,_=8&-1S^!(_&L[XM_#OX??#?3
M?B=XKOO@YI1T_P '16UOI6GS/+%;ZJ)Y%!N']=N"HQD=:T?^"ISK#X1^%D[G
M:D?B-BQ/8>4"3^E4OBCXD\)^-]/^*'AO7/B18Z5I_P 0(+6^T"^NTGEBM88)
M /F^7"JY5R%'H2<9&?K<"ZD<'2<6U'6]N;^:-_AZ\O-OTO;6Q[]%R5"%F[:[
M7[J^WE??I?J96O\ [-'PM^&VK^-_BK-X7>]\*Z=X4L=;L_":W3I;_:;C<&5F
MSN*#:N >!N/L*Y3Q#X$^'?C;]FNY^(VF?#_3/"VLS>);*S5;"61A'$6C61 2
M>C9.>.]=9XH_:>^$WCG7/&'PFO?%OV#PMJGA*RT2Q\5"V=[=KJ#>6;:!G;\R
MX/0[2,]#5[1]#\$:)\ 9?AQK'Q&L+&UEU&TUZQ\2FSE^QWT2.N]8AU)#1LOU
M]:[,/7J0I1=>4_:*<+?%\%FY:+2^U^OXFU*I)03J.7.I1MO\-G?R[>9S'[3G
MPG^'?PK\%?$K5_"WPVL?$VH66J1Z??H;J56\/6TEFC0W,: DD&1MQ)R,GG@5
MRG_!&^ZEE\=_$56D8YTR MSU(G(!_4_G6YJOQE^%FL?&/XF_%:#XE^7I=[:7
M6B7'A!].F9]8B2T$43CC&TR98;@"-N> :YS_ ((S_P#)0/B(/^H9%Q_V\5X]
M651X>:JMM\JNW?>\=->W=?YF4Y3>'<9MO3K?R[G'_L6>%]-\7^,/C=>:MX0@
M\>7^B137>G:9<AVWS&[*G 3DD@GUZ5]'Z?\ !_X5:EX]\$?#+4OAO8B]\9>&
MI]=GUI;B47%A.P9EBB&<!4Q@9]!G/-?-7[%NN6]GXY^./AV/6ET77_$2SV&D
M2%WC+SBZ+-AU&5VH&8GT!KZ:T?XJ?"W3O&W@+XF:E\1K#[7X+\,S:%<Z.EO,
M;B^N I"/%E1E6#$C//(SCFO#J.7GMYGT:GB/8^Y*6VEN??E]W;W;<U[>:=SA
M)/AY\/\ X&?"_P ":-KO@N'QUXF\3V5Q>76HZK<NJVJAPBK$B\#&X?\ ?)R>
M:Z7Q-\!_ASIOQH\>^'WT"WL?#>G^ ;?5XXHV?;:W!D >X4;OO!<GG(XZ5B>'
M_&O@;]JOP%X!DB\7P^'/'/AR"?3KC1+VUD=KHM(&01%>"257'/\ $00,5V'Q
M<^*GPRT[4O&'C&]\;Q0ZIXA\'P^$SX9^R2&[M9R^UW<],+DYS_=/)XJI2]U6
M;YM;[]U8]*K7FZ5/V<Y^U?.I_'_/'DMTMRWM;3N?+?[7NE:3X,^-FF^&M \&
M6_A/2=.\F:PU"TN7E&L6[F,Q71))&?O#Y??/2OV+@):WA).28U)/KP*_';]H
MK6O"MIX;^%G@O0_&R?$*]T"YNBVL16KPK!:R2Q^3; OR=I5CC) SCBOV(M_^
M/:#_ *YK_P"@BN)I1@K=V?/\02G*CA^=MM<RN[W=FM?>UUWL]KGS3_P4>9E_
M9)\4 ,5#7=B&QW'VA>*^7_V;?AIH'B[]G#P=J%WX!M?$FJ>(/$4VC:AK\GF>
M;IEOO1$E!!P"-Q R,9Q7U!_P4>&?V2?$_P#U^6/_ */6OE?]F/QUI]C^S?X+
M6+Q1%I3>$/$LNMZ[9L909+5YD$*%44AR[ [0> 1DXKQL2HNM[W;R[^9Z622K
M1RVU%M7F[VYOY5;X==VDNEVKZ'5^)_A!\-?BU8_&GPEX<\ V7@_6_ -W;P:;
MKEC/(TUR#)L8S!C@YPW'N*Z&;X??"'2OC[HWP43X:66JI936L5UXBU*ZDDNK
MAS%YCY&<8(P.HZ\#BL/Q;\7?AI\'-+^-?C30?'ECXMU;QY=6]UINB64,BS6Z
MA][^:6&!C+<^PKJ=.\2?#CX@_&^T^.WA;QM'J%N%MK[4?#8LY/MMLJ1B*5SQ
MC:BD,?H<$Y%83BO=<$KW5]OAN[_A;S/4P]::]K'$2J>S<)<NL_XO)'EOUMS\
MV_NWN8GPS^ WPUUNY\01ZSX?M)#:_$2\TC3899FC65$MG>"R+9X1G 'KVSS7
ME_[#^J/>_P#!0:X5?#:>"U33M0AE\/0LS)9.@57C!;G&Y<\^M=U\5-:^%EWI
M=[X$M?B_8V]]XD\9W'BQ=8M[.4QZ4%A)C20CG=OVC(.1UP,52_9T\8:+X\_X
M*=7.L:#?C5[)O#TL+ZH(3$+Z:.WBCEGVD C>ZD\]:NG&"J122T?2W]?\.<>,
MKXB>&KNI*;4HO27-I:W?377S7+V9Y;^SGHEAXW_;F^(>F:YIL>OV2RZQ=+8W
M&2))D<E.G.<\?C7UAJ.@^"?#EEX.N=;^'%A<W'B[7VTJ6QFDFC738EPA\M2<
MAL\G/J?:OD/]G/Q1IOA']N7XCWNIWZ:=%*^LVL,S9YGD8K&HQSDL0 :^P+^^
M\(:C9^#=+\3>.]/T74_!GB!]2N_M*RR?:4)RR(Y&68,-I/L<9XKQJT:?,M%>
MW7EW]WOK>W-;IO?6QY&+E5E"ES-VY5WV][:WG8A;X3>$O@1IWB/4+O2)/$PU
M#Q3_ &+IFG7UTZVUM 5# L%^\0-W)]O>M>+X1>#(?%/PO6U\.6ME%K;7IO[>
MVDD5+C:'*JWS9(&!BN>?XZ> ?CH/$/AV[\2Q>%]4L/%/]LZ7)J,+^5=V^ JY
M('RDC=P>1Q7?ZKXV\(^$K?PGX@\1>)(=';P<;U9K.:VDWWI96V&'CHP8$9[$
M=*XE1I2KM14/8VC;X=^>\O/X4_)K8\[FFH:WYM>_\NGEO^)\;_MV:9HG@SX6
M^$K?PWX?A@L[^!;I/$\<S/)>.-XF@8'@;&QQU&!5[_@J+J=U9R?!>2.9ED'A
MZ,Y//)*9/Z"L7]J+7_"EA^RM;Z'IWBZ+Q1?:MK,.LVEE';NATM#&QG5F/&6+
MJ"!UQG%:/_!508NO@RH[>'X_YK7JX:$70E9)7MHK6Z::?\/WU.N,Y*K1NWIS
M:Z_J?1]A\(_!D6L2Q77PVM+?0M(\.KKW]H*TR_VM*+56>%F)QM#ODA><@5C>
M#_@!X"^.,7PI\;V_AQ?"5CJ:WLNKZ5I=P_E2>0"4"L>5R1R1CC\ZU]&^(GAR
M36KK6=0\8P1^$?$/AM= M&/G.MO*MLB2R[-N%42?*3U)]N:R?"G[0WP[^ =O
M\*O!;>*8?$>E:7%>PZSK>G0OY$+3@A, C)P2<XR0*F,<,W[ZCR_]N]U;;I;\
M-Q3EB4KQ<N:W][L[[Z7O;Y[%/X<6_P .OCYHWCC5!\-],T>'1=-N?L)$\DLA
M*OM21B3@. .WK6M<?#'P/H7@.WUNW\'VGB7Q!;^$(=1_L:XGD"SQM,RSW.T'
M+,JA>G3\:/@3X>\&_#C3/%6GZ?X]L=?\/>(8;JSM]9M;>3RK.0MYB1SG^\58
MGC^Z>E43XX^',GQK\(7EM\3[6S?X>:)%87:K:2%=6C<NT\<?KP%4@Y!W>U<]
M*E'EBZJCS:K[.EY:.VVD=?PW-ZM27,U2<N71_:UM'57WUEI^.Q9_X)COOTKX
MD;3B(WEFRIG@923^F/RK[=KXN_X)M3075O\ %.XMH_)MI=5@>*/&-J%92H_
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M#DHKFD[)&:5]$9QZ5^Y?[''_ ":O\+O^P)#_ #:OR2G_ &?=2\)KN\5,MO=
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M5:HJ=2,>?W7:^J4Y1C&]N[DNNQ\N?!__ ()GRR307FL@6$((8W6J();AO>.
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M42.ZC2RMT7 &< *0_P#X[3_V4OV4?''Q+\/7<<=O'X<6SN!'<_VQ'+#,C$9
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MB+;22,C=CDUTGB*Z\1/\)M(B-_H$WQO73KL:;+)-:-*K_:8_,4O_ *O[7Y.
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MY+!Y(=/2XW&W1&;";W5&9GSDX/8"OHCXAVD^I> /$MI:JSW,VG7"1HO5CL/
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M3?[MRD>R=<^WZU](?#7X1>'? ,23VMM]LU,#YM0N@&D_X .B#Z<^]?:XKBG
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MKP23)\2"/^S_ -\GF1?-O0C.Y=IR,>XKR^8_#2[MG$^BW%JB(LD@:WEC &5
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M=S*9KB.6Q6TMG<G.X*,?,/7.?>NFTCX<^(XM-ATW2M,TOPUIL?"00 OM_P"
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M*;'BE!_MC^=?9VGC_BGX_P#KE_2OB[P9QXMC_P!\?SK[4TY?^*=C_P"N7]*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ea029095401_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029095401_img3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $% NT# 2(  A$! Q$!_\0
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M_6LSUK4T+[UQV^[_ %IK<PK_ ,-E"Z_X_P"Y_P"NK_\ H1J!N34MV<7UR?\
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MF26&#B@,P'&*.1!_;V*_EC]S_P SPS_A6WB0?\P[_P BK_C0/AOXDZ?V<?\
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M'N32_:2<8_2IAYXZ>$;S_P #%I6,Y_YE"]_"]2BP<T>WY?YD!GR1DFD,_O\
MK5A#.>/^$0O./^GU*0_:.O\ PB-[_P"!J46#G7]6_P R&VE<WEOL;:_F*58=
M0<\&K47Q)\3./FURZ_!A_A5G1H9)-7LP=!FL290NZ:=7 _"N3M+&[;[MK+(
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M].,*U AN<GJ*4GW6I$^Z,@*?:D7:2#C!H&,Z]QFE/'?/L*?@-UP11L7\/K2
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MR!^%2"/)Y)I3$!QDXHL T'Y,X_"F*Q)Y4@5,(0R]30;<=B:+ ,!7W_*@X7U
M^E.2$*<\T;'!_'UH ;O4#&[%*)$Z;A1Y1!Z YH,?^Q^5 #<QCD;:1A$>^/H:
M0HA!P,&F^3TYYI#%$>3D-QVHV/W II3 R.:  0* %P>XI#UZ9%&0">,T$G-,
M!-HQSUIK9['-2 G I&&!TH ;GY>12$^P/XT9 / H(&,D4#&DD$]A1DC.:3D=
M^*0!NF1]* %##&.*<"0:BQ@X[TK<#FG85R4M@XXR:;NS^'O4>X,>>M(1QZ4
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METZQAW+PNQP,GJO^%:(^9S2E.>&?)T=_D=)XRTG2[VS\_4)1;/&,)/\ Q#V
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MO.+?=]GDE4EHL]<=C[56AQU88QQ]S?3MVUM\[?(NC38H]-NKJ:[>*:VF^SO
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M5F.!42E&$7)O0ZZ4*N]5]%]]M?Z_,Z'P"0WQ$T8_]/)Q_P!\M7@+R 3W'?\
M?./_ !XUVG@7XR6]S^T+X1\-:/(DT4M^\%](0?,W*C$H,< #C.:\]-QON)P.
M\S_^A&O.PF,6,A*<8VBG97ZJV_EY'934HUY.2M>,;??(V["ZV2@$YYXXKOO#
M6H$28R1D8Y%<AX&UB'23JL\\LT1%NH0VSJLN3(OW"P(SCK[9KL;*1M6T+19H
M[VW\V.:X\X7$ZB4%Y1M)'?CDGZUZ"V)G7M+DE'2]K_*__ .UM9B0NW))YP!F
MM*-SG:5;)Z J<_E5V'4]-SI<NFZE$LEA,EN616C9H3C))/7D,21V:MW1M>MY
MK_7))KU8;Z:3;:W<KX"1AC@!N>!UQWZ55CR98J?*Y*F_QOO;MVU,ZT\1:M;Q
MB.VOKH1CC:I+8_/.*J7-[<7D_F7$LL\AR<R$G\JVY?$D::UJ\MC>F*)[(A9(
M_P!VLTX &\+V/7%$=] 8;*^>\B_T>QE@DA9OWIE8,!QW!W YJC-3Y??]G:_W
MZJ]GI\CG7E)QC//2JTK9R3T'>NQL;K1K.'23,R23Z?'&F <K(9.6S_N$FLY!
MH\>DM:WDZ';<378DC.3M1L"/_@:CB@U6)M]A_P!7_2S^=CCUNMDC<XK+O[A)
M:Z]]8M1K^J$I;36,]L-0AAD(VQS",%5!^N05[UP-[>274TLTQ#2R,7=@,9)J
M6=U"3J.[C;1/[^GR.S^%&/\ A*W#9*?8I\[3R1M[5R(2V'+:A;0@]%EDY'UX
MKI?A1JFGQ?$*/2Y+M%U.73YY4M1][9MY<^@KCYY;G.V&*Q89ZS6X<US4<13Q
M,7*D[I-J_FNPZ3YL35:[1_\ ;BY_H@ZZM9?]_*7_ $+'_(6LO^_E10:7K-T
MR0:7M][,597P]K;=4T@?]N@KH.YNW49_H9_YBUD1_P!=*3;9X_Y"UE_W\J7_
M (1[6A_!I'T%F*NK\/\ Q:\#3KIEDT/][^SZ:,Y5(1^*27S,MA9#'_$VLO\
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M 7&0#7I/Q3N$U'Q+Y<>"EI$(2?\ :R6/\Z\_NH<=>G>I>Y]9ESDL+34M[?\
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MPVV]ZP]/+ _K77:#\:M(1E(L+YNW 3_&M$XG5.CF\_Y_O_X)ZQ;?#;PT2/\
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MO[UVOA)?$%XG_$ET_P"T6<; %S$N <= Q.0/;-<+X>6UFDF-TB.JKQOG\O\
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MU!O33+O_ -$FO,8I JKSVK[EGEX>"A.279?J=W8:U;06,2&[=& ^ZJR<'\&
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MZ--S2MRV//J8.I&HFW?T7_ M]XY_@CX>\*_;=:TRQU35;2[MR+6W\N=T5BI
M=7,I P<&O)M2M9M-$:7,3PR<@B12"2.M=3JNN?&0Q/<)::+:W"WC3?98K@E6
MC(Q@,3QS[5:^"EEJ?C/Q9?67Q>E@G>]N;>/3K:/+^>Q#*R[XR"F/EY/6FI.3
MMRL]*$)X:C.M4=TNB6OR25CF/#<L)G,31&=W/RJL0D)X]Z[?1?AO8>.?M\=Y
MIEU#%$D;QWT4)"JP8';\LBCD9'-=5\?_ (;6'P_\+SQ?#O3[>Q\87D7EV:7,
MLC1M&9$$K%G8A2$W8]=U>+7WPQ^*GB&:QOVEMM,: (196NI;80PQDCUW<_>S
MZ4592AM&Y&'4<QI^UA+D3[KM^!Z[)\#? OAN1;OQ%HMX\+M^Y^T7KP),0,]1
M*2/7O5_Q'X0^#M_;Z8BZ3_9'G;E3[/>22@G//S+(">>,G%<G=I\2]1^Q6X\/
M>%]-\N>)GOHIC)*$!^;"],D=AUK1T_2?B)X9NKW6#I6@ZO?/*#%;SH;8*AW9
M;=D@D?+VYJE*36D3S)8*I"HFW?Y?\!K[SH5^%'AKPD#)IVD7%S/*R21;RY:-
M0#\RYD.X'C@9-6+.R26+S]-NY;?/#"-B,'N"IZ'ZBO.9-4^*4)BN9M/T.:0^
M<D]J'!&UN4*L<X*G&,>IKMO@CIQ\2V5U8>+9I].U^:[EGAM],N&4&$*#EG&1
MUSQ]*XG2=>7LZL%*#Z-?YWO]R/6DI87"RK5?>2[+7[NQIW":NP_>7$%R!T%Q
M"'%9EY8:A<JR&TTX%ACS$L5W#Z9S7<>-/!EEX7\/2ZAI]WJ37<<B*IN+LR+R
M<'@CFLG0KW4I-K27$I[]:R>58.+^#[G)+[KV_ >"G2QM%UJ4;).VJ.4T+P(N
ME7?VO8QN?^>GE\_A@<?A73R+(4/[F3_O@UN'7-6@8B.^N$7/0,:DBUS59&&Z
M^N&^KFN^E3I48J%.-EV1WM5>R^]_Y$.B!X[74R8W'_$KNL?*?^>1KR:.1RH_
M=R#Y>Z'_  KWO2;Z]G+>9/*X Z,37-:[K6IVUQ(J7<R*#P >*V;1C3<_:2T[
M?UL>8KKD\$21K$BA!C<5;)]SS3/[=D<?-!;R-C!9T)/;N3[5U.IZ[J9C.ZZD
M8'UK-\");>*M9\10:JAO#8V(GA!9EV,21GY2,].]3N[&E=QPU%XBHM%;;S=O
M(P[VZ.IQ&)K&/8V0_DQ'#@]CUJCH\6L>'X19VL8OM)&=EEJ$$A\K/4(ZX('M
MTKT7P]J-Z]I 3._*CIQ73MJ>H6ZJ8[J:,X_A<BN:OAZ.)CR5HW1M6HNWLY)-
M?U\SQ73AK7AQ[J305%C#=,7N-,:S:6TE;')*MSGW!%9%]I,>H>=+=> M%6Y/
M+31P3;6/KLQ_6OH$:]JC#YK^Y;_MH:T+'4KUI%W7,S ^KFM(4J<(J$5HMNOY
MG$\/"*TII>C:^^UK_.Y\O7%_J+68LULWMK5,8M[2S:*('UP!S^)--T9+A;LE
MK:=<J>L3#^E?4'BB_O;=$,=S-&3UVL17%7>L:B6YO)S]7-::'303<4H121['
M^R0Y/PSO%.5(U.8888[+7H'BB_MK74D2:XAA8Q@[9'"G&3VKY=\'^*=7TGQO
MI,EO>2(#*0T9)V."IZCO6_\ $O7[CQ!KT5Q>F-IUMU0;%VC&YO\ &M5+0^1Q
M>5NIF7)*5N=<VVWD>WP:YIT<J,U]:@ Y/[Y?\:X;3M.N9/"4VAS3:3:2VNH-
MJ5G>/J*RQ7#K=F=$DC #*I& 3S@_2O)(=JD' XK(G\)ZQJ5P\C^(+JWC9V9$
MM4\O:K,AVYSR %8 ]?G--2*J9!&"TFW]R_-GT5K$=SXPCU>\OKG2-+NI-(FT
MVTM$OQ-N:0AF>20  +E0 ,'')/6KNK:Q=7Q\-:@L>DQWFDW+L]FVJIB1# T8
M(DVX!R>F.@KY_L/!=\L/[S6;YWY!?S7&1OW<C=@''R\8]JF_X0S4A;O&FM7B
MLT\<JR&1F955-I3ENA//U/.:JYS?V)'N_O1[=XCT^'Q =?D_M;3[0ZH-,VB.
M]PT1@D+2X8#@X/RD=3Z5/=6>F>'[O2]0\-7^G2W%D]SYUOJ%Z<W8GV&1S*=Q
M$F8T.XY!&1Z5X'_P@&J3,9)O$6I>82"1%+MC& < #/3)S[XQ48^'>M)&B_\
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M#Z&:3EBY-T6W=I6:;>]K[-_,P/A?X4C\.>"Q:QR+/K98SZG;L")%?&,H/XD
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M7+<#%=%8+A/I7T1\8:,28 (Z5=B7 &3TJM IP.*MQC$?J32!CSC.*;CK_6G
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MTVRR#]:NQKP#4&M#;XHO1_TV>K4 R!2/K*3<J4&^J7Y&K8Z/>W4*R0VDDD;
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ML*,U!;\U8S[4(0$<TH&*3.>M'2F PP@CTS[4QK16XS^@HHI6 A?3=_20#_@
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MW_#M7(_Y*0__ ((Q_P#'Z**:P])*RB9O&XAN[F1-_P $R0YR?B7)_P"",?\
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/TXBBBJ$"C.:7:*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ea029095401_img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029095401_img4.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $0 9X# 2(  A$! Q$!_\0
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MY W) 65GFVME2X4+E3@FNH\$?'>6_P#%=IX0\<>%[SP%XNO$>2RMKF9+FSU
M(,N+>Y3Y78#DHP5@.<$<UD?%>ZUSP!H_PV^'/PZOK;PY?:M<'3+;4)K1;E;2
MVMK1Y&(C/!)\M%R>FXGK7#_$+Q?J7Q/_ &)[#XD20PV_B[0[:'Q';R1+A(KZ
MSE/F%1_=;9*N/1R*E4X5+6BDI.R=W?6]F^G1] YFNNJ/3?&OQXN;7Q7>>$?
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MAL^^:XZL5RN/\MFNZOT-(O5/N>U4445YYL%%%% !1110 445\\_'G]N#X=?
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M44 %%%% !1110 4444 %%%% !1110 5^?'QIT6Y\1_!/XYZ39!3>7_Q3CM8
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MS'D^BJ.BJ!P%' %8M%%?H,8J*48JR/&W"@C(HHJ@&G)I<&E)"@DG '<U]&?
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M;!=,1V=D&\?@V1^%=;7Y+*+BW%]#Z).ZN%%%%2,**** "BBB@ HHHH ****
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MHQ_\<6OOZOR_,H>SQE1>=_OU/>H/FIQ84445YAN%%%% !1110 4444 %%%%
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M00I?:3>2V4P/K&Q7/X@ _C617V)_P4Q^$A\(?%VP\:6D.W3?$\&V=E& MY"
MK?\ ?4>P^Y5J^.Z_5\)76)H0JKJOQZGSU2')-Q"BBBNLS/=?V+_C4/@C\=-)
MOKV?R= U?&EZF2?E1'8>7*?]Q]ISZ%J_9@$, 0<@]Q7\^3*&4@C(/!K]9/V
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MTKQ)\1[V'#WK?V3IS,.?*0AIG'U?:N?]@UYN8XCZMAISZ[+U9M1ASU$C[Y'
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M))]S7/*JEI$^FP62SFU/$Z+MU^?8O:UKEYX@OFNKR7>_15'W4'H!5.&9H7)
M5@RE'1U#(ZD8964\,I'!!X-,HKEN[W/L53@H>S2]W:Q\8?M/_LI#PQ%>^-?
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M9)KU^;X-> Y];M-9;P=H:ZM:2>=!?1V$231O_>#A0<^]6I_AKX>F)(L?*/\
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B=^ OAIX<\.W\L,]YIMFEO+);DF-F'=<@''U%3?0JVI__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ea029095401_img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029095401_img5.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !7 : # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBD) &3P* .-^)WQ-L/AKHHN9U^TWT^5M;13@R-W)]%'<U\TW7BCX@?%[498[
M5[Z[CSS:V.8[>(>C'('XL:M:Q+<_&_XS?94F9;-YC!$P_P"65M'G<P'J<$_4
MBOJ[P_X>T_POI4.G:9;):VD0PJ(.ON3W)]:]!J.&BM+R?X'PB5?B"M.U1PH1
M=M-Y/^O^&W/E1/V?O'UHHNHK2))ASB*\42?GQ_.K?A_XN^-?ACJZZ?K\=U>6
MZXWV>HY\T+ZQR'G]2*^L:Y/XD^ ++X@^')[*>-5O$4O:W&/FBDQQSZ'H167M
M^?2:T.B>0/"1=7+ZLHS71O1^6R_R-;POXGL/&&B6^JZ;-YUK,.,\,C=U8=B*
MUJ^8OV;?$MSH/C*\\-W19(KL/^Z8\)/'U_, C\!7T[7/./*['O99C?K^&55J
MTMGZH****@]4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3TPVY["XD4G_ (%C'Z5[C\(/V4_"'PWTZWGU*R@\0^("H:6]O(PZ(W<1(>%
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M^^U2?Q<>E2WK9%Q2LVSK?BQXLU3XK?$4>'M,)DLH+DVMK IPLD@.&E;\CSV
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MC\Z'NAKX6?8M%%%69!7Y_P#[6X _:6MB  2MAGW^85^@%?G_ /M<?\G*VO\
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M=17?B"_N?$TL9#"W=!!;9]U!);\3CVKZ/M;2"QMHK>VACM[>)0D<42A511T
M X HHII6);;W):P?'?AF;QGX0U70X=1ETEM0@-NUY"@9XU;AL ]R,C\:**8C
M@/@5^SEI'P-FU6YM-0GU:\OE2/S[B)4,<:\[ !ZGD_05Z[112M8;=]6%%%%,
#1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ea029095401_ex5-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029095401_ex5-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ 1<# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"/_A77BO\
MZ!+?]_D_QH_X5UXK_P"@2W_?Y/\ &O<-?N9K+0KNYMWV2QJ"K8SCD5Y^OBO7
MWSLNF;']V('^E>E3J5:BNK'#45.F[.YQ_P#PKKQ7_P! EO\ O\G_ ,51_P *
MZ\5_] EO^_R?_%5V7_"4>(O^>\O_ 'X'^%-;Q7KZ8WW3+G^]"!_2M/WWD9\U
M+S../PZ\5X_Y!+?]_D_QKWVU1H[2%&&&6-01Z$"J'AR[GOM"MKFY??*^=S8
MSR:U:X*U24W:70[:4$E==0HIKND:%W954<EF. *4$, 000>016!J+13(YHI2
MPCE1RIPP5@<?6HVOK16*M=0!AP09!D4 3T5'%<03DB*:.0CKL8''Y41SQ3%A
M'*CE3AMK X^M $E%%59]2L+6417%[;12'^"255/Y$T 6J*165U#*P93R"#D&
MH[BZM[2/S+F>*%/[TCA1^M $M%0V]W;WD?F6T\4R?WHW##]*D:1$959U5F.%
M!."?I0 ZBFNZQJ6=@JCDDG %".DB!T964]&4Y!H =1134D25 \;JZGH5.10
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C&FOV[^&M#DTN*)6\V[9/+!...G'MQSS11.*>\K>H1;Z(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>May 14, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001562733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Synergy CHC Corp.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>May 14, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">101,710,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 30,513,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 4,213.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Consists of up to 101,710,000 shares of common stock, par value $0.00001 per share (the &#8220;Common Stock&#8221;), of Synergy CHC Corp. (the &#8220;Company&#8221;), comprised of: (i) up to 100,000,000 shares of Common Stock (the &#8220;ELOC Shares&#8221;) that the Company may sell to Hudson Global Ventures, LLC (the &#8220;Selling Stockholder&#8221;) from time to time pursuant to the Purchase Agreement, dated May 8, 2026, by and between the Company and the Selling Stockholder (the &#8220;ELOC Purchase Agreement&#8221;); (ii) up to 1,540,000 shares of Common Stock issuable upon the exercise of a warrant issued to the Selling Stockholder pursuant to the terms of the ELOC Purchase Agreement as a commitment fee; and (iii) shares of common stock previously issued to the Selling Stockholder in connection with the consulting agreements between Selling Stockholder and the Company.<br/><br/>Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on May 13, 2026 ($0.30 per share of Common Stock). This calculation is in accordance with Rule 457(c).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>May 14, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 30,513,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">4,213.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 4,213.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea029095401ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea029095401ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea029095401ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="ea029095401ex-fee.htm">ea029095401ex-fee.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea029095401ex-fee.htm": {
   "dts": {
    "inline": {
     "local": [
      "ea029095401ex-fee.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/ffd/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 1
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 21,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea029095401ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea029095401ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea029095401ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea029095401ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea029095401ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea029095401ex-fee.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001213900-26-057939-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-057939-xbrl.zip
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M8X05(X^I%H'H+S\95?T(VC K&TC/5]: ,M8!>G=4U;6@UL-U\&:8#M].56O
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M839-=0KOV<5E$]THN!@W$@,LD(2)B(+/C!$'3Y3X?PLL#IC.;:\+N]X]<47
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F,#DU-# Q97@M9F5E+FAT;5!+!08      0 ! $,   !G"P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>ea029095401ex-fee_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c_offering_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001562733</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-14</startDate>
            <endDate>2026-05-14</endDate>
        </period>
    </context>
    <context id="c_report">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001562733</identifier>
        </entity>
        <period>
            <startDate>2026-05-14</startDate>
            <endDate>2026-05-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c_report" id="fee_001">S-1</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c_report" id="fee_002">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="c_report" id="fee_003">0001562733</dei:EntityCentralIndexKey>
    <ffd:OfferingTableNa contextRef="c_report" id="fee_004" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="c_report" id="fee_005">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="c_report" id="fee_006">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="c_report" id="fee_007">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c_report" id="fee_008">Synergy CHC Corp.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c_offering_1" id="fee_009">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_1" id="fee_010">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_1" id="fee_011">Common Stock</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_1" id="fee_012">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c_offering_1"
      decimals="0"
      id="fee_013"
      unitRef="shares">101710000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_014"
      unitRef="USD">0.30</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_015"
      unitRef="USD">30513000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_016"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_017"
      unitRef="USD">4213.85</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_018"
      unitRef="USD">30513000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_019"
      unitRef="USD">4213.85</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_020"
      unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_021"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_022"
      unitRef="USD">4213.85</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c_offering_1" id="fee_023">Consists of up to 101,710,000 shares of common stock, par value $0.00001 per share (the &#x201c;Common Stock&#x201d;), of Synergy CHC Corp. (the &#x201c;Company&#x201d;), comprised of: (i) up to 100,000,000 shares of Common Stock (the &#x201c;ELOC Shares&#x201d;) that the Company may sell to Hudson Global Ventures, LLC (the &#x201c;Selling Stockholder&#x201d;) from time to time pursuant to the Purchase Agreement, dated May 8, 2026, by and between the Company and the Selling Stockholder (the &#x201c;ELOC Purchase Agreement&#x201d;); (ii) up to 1,540,000 shares of Common Stock issuable upon the exercise of a warrant issued to the Selling Stockholder pursuant to the terms of the ELOC Purchase Agreement as a commitment fee; and (iii) shares of common stock previously issued to the Selling Stockholder in connection with the consulting agreements between Selling Stockholder and the Company.&lt;br/&gt;&lt;br/&gt;Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on May 13, 2026 ($0.30 per share of Common Stock). This calculation is in accordance with Rule 457(c).</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
